Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 1Title Page
APhase 2b Randomized, Double -Blind, Placebo- Controlled, Parallel Group, 
Dose -Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen 
(PF-07285557) in Statin -Treated Participants with Dyslipi[INVESTIGATOR_19921]: Vupanorsen (PF- 07285557)
Regulatory Agency Identifier Number(s)
Registry ID
IND 137,[ADDRESS_18779] 2020 -002796 -35
Protocol Number: C4491011
Amendment Number: 1
Phase: Phase 2b
Short Title: A Phase 2b Dose- Ranging Study with Vupanorsen (PF -07285557) 
(TRANSLATE -TIMI 70)
 
 

Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary and Rationale for Changes
Amendment 1 18September 2020 Section 10.13 (Appendix 13 ): New 
appendix was added describing 
alternative measures that may  be 
allowed during a public emergency , 
such as COVID -19.
The Protocol Summary  was revised as 
appropriate for consistency  with 
changes in the bod y of the document.
Title page, Schedule of Activities , 
Section 2.1, Section 9.2,Section 10.14
(Appendix 14): Administrative changes 
were made for clarification .
Original protocol [ADDRESS_18780] of country  health authorities and IRBs/ECs.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
1. PROTOCOL  SUMMARY ................................ ................................ ................................ .....9
1.1. Sy nopsis ................................ ................................ ................................ .................... 9
1.2. Schema ................................ ................................ ................................ .................... 14
1.3. Schedule of Activities (SoA) ................................ ................................ ................... 15
2. INTRODUCTION ................................ ................................ ................................ ............... 19
2.1. Study  Rationa le................................ ................................ ................................ .......19
2.2. Background ................................ ................................ ................................ ............. 19
2.2.1. Atherosclerotic Cardiovascular Disease ................................ ..................... 19
2.2.2. Hypertrigl yceridemia ................................ ................................ .................. 20
2.2.3. Rationale for ANGPTL 3 Inhibition ................................ ............................ 21
2.2.4. Clinical Overview ................................ ................................ ....................... 21
2.3. Benefit/Risk Assessment ................................ ................................ ......................... 22
2.3.1. Risk Assessment ................................ ................................ ......................... 23
2.3.2. Ben efit Assessment ................................ ................................ ..................... 25
2.3.3. Overall Benefit/Risk Conclusion ................................ ................................ 25
3. OBJECTI VES AND EN DPOINTS ................................ ................................ ..................... 25
4. STUDY DESIGN ................................ ................................ ................................ ................. 26
4.1. Overall Design ................................ ................................ ................................ ......... 26
4.2. Scientifi c Rationale for Study  Design ................................ ................................ .....28
4.3. Justification for Dose ................................ ................................ .............................. 28
4.4. End of Study  Definition ................................ ................................ .......................... 29
5. STUDY POPUL ATION................................ ................................ ................................ ......29
5.1. I nclusion Criteria ................................ ................................ ................................ .....29
5.2. Exclusion Criteria ................................ ................................ ................................ ....30
5.3. L ifesty le Considerations ................................ ................................ .......................... 32
5.3.1. Contraception ................................ ................................ .............................. 32
5.3.2. Dietary  Restrictions and Fasting ................................ ................................ .32
5.4. Screen Failures ................................ ................................ ................................ ........ 33
5.5. Criteria for Temporarily  Delay ing Enrollment/Randomization/Study  
Intervention Administration ................................ ................................ ...................... 33
6. STUDY INTERVENTIO N................................ ................................ ................................ ..33
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 46.1. Study  Intervention(s) Administered ................................ ................................ ........ 34
6.1.1. Administration ................................ ................................ ............................ 35
6.1.2. Medical Devices ................................ ................................ ......................... 35
6.2. Preparation/Handling/Storage/Accountability ................................ ........................ 35
6.2.1. Preparation and Dispensing ................................ ................................ ........ 37
6.3. Measures to Minimize Bias: Randomization and Blinding ................................ .....37
6.3.1. Allocation to Study Intervention ................................ ................................ 37
6.3.2. Breaking the Blind ................................ ................................ ...................... 37
6.4. Study  Intervention Compliance ................................ ................................ ............... 38
6.5. Concomitant Therapy ................................ ................................ .............................. 38
6.5.1. Prohibited Therapy  During the Study ................................ ......................... 38
6.5.2. Prohibited Prior Treatments ................................ ................................ ........ 39
6.5.3. Rescue Medicine ................................ ................................ ......................... 39
6.6. Dose Modification ................................ ................................ ................................ ...39
6.7. I ntervention After the End of the Study ................................ ................................ ..39
7. DI SCONTINUATION O F STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ................................ ................................ ........... 39
7.1. Discontinuation of Study  Intervention ................................ ................................ ....40
7.1.1. Monitoring Criteria ................................ ................................ ..................... 40
7.1.2. Discontinuation Criteria ................................ ................................ .............. 41
7.2. Participant Discontinuation/Withdrawal From the Study ................................ .......[ADDRESS_18781] to Follow -up................................ ................................ ................................ ....42
8. STUDY ASSESSMENTS AND PROCEDURES ................................ ............................... 43
8.1. Efficacy  Assessments ................................ ................................ .............................. 44
8.1.1. L ipi[INVESTIGATOR_805] ................................ ................................ ................................ .......... 44
8.1.2. Lipoproteins and FFA ................................ ................................ ................. 44
8.1.3. hsCRP ................................ ................................ ................................ ......... 44
8.2. Safet y Assessments ................................ ................................ ................................ .44
8.2.1. MRI -PDFF Assessments ................................ ................................ ............ 44
8.2.2. Physical Examinations ................................ ................................ ................ 45
8.2.3. Vital Signs ................................ ................................ ................................ ..45
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 58.2.4. Electrocardiograms ................................ ................................ ..................... 46
8.2.5. Clinical Safety  Laboratory  Assessments ................................ .................... 46
8.2.6. Pregnancy  Testing ................................ ................................ ...................... 47
8.2.7. Potential Severe Cases of Hy pertrigl yceridemia ................................ ........ 47
8.3. Adverse Events and Serious Adverse Events ................................ .......................... 47
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......48
8.3.2. Method of Detecting AEs and SAEs ................................ .......................... 49
8.3.3. Follow -up of AEs and SAEs ................................ ................................ .......49
8.3.4. Regulatory  Reporting Requirements for SAEs ................................ ........... 49
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ................................ ................................ ................................ .......... 50
8.3.6. Cardiovascular and Death Events ................................ ............................... 52
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualify ing as AEs or SAEs ................................ ................................ .............. [ADDRESS_18782] ................................ ............................. 52
8.3.9. Medical Device Deficien cies................................ ................................ ......53
8.3.10. Medication Errors ................................ ................................ ..................... 54
8.4. Treatment of Overdose ................................ ................................ ............................ 55
8.5. Pharmacokinetics ................................ ................................ ................................ ....55
8.6. Pharmacod ynamics ................................ ................................ ................................ ..56
8.7. Genetic s................................ ................................ ................................ ................... 57
8.7.1. Specified Genetics ................................ ................................ ...................... 57
8.7.2. Banked Biospecimens for Genetics ................................ ............................ 57
8.8. Biomarkers ................................ ................................ ................................ .............. 57
8.8.1. Banked Biospecimens for Biomarkers ................................ ....................... 57
8.9. I mmunogenicit y Assessments ................................ ................................ ................. 57
8.10. Health Economics ................................ ................................ ................................ .58
9. STATI STICAL CONSI DERATIONS ................................ ................................ ................ 58
9.1. Estimands and Statistical Hy potheses ................................ ................................ .....59
9.1.1. Estimands ................................ ................................ ................................ ....59
9.2. Sample Size Determination ................................ ................................ ..................... 59
9.3. Analy sis Set ................................ ................................ ................................ ............. 59
9.4. Statistical Analy ses................................ ................................ ................................ .60
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 69.4.1. G eneral Considerations ................................ ................................ ............... 60
9.4.2. Primary  Endpoint(s) ................................ ................................ .................... 61
9.4.3. Secondary  Endpoint(s) ................................ ................................ ................ 61
9.4.4. Tertiary /Exploratory  Endpoint(s) ................................ ............................... 61
9.4.5. Other Safet y Analyse(s) ................................ ................................ .............. 61
9.4.6. Other Anal yses................................ ................................ ............................ 62
9.5. I nterim Anal yses................................ ................................ ................................ .....63
9.6. Data Monitoring Committee or Other Independent Oversight Committee ............ 63
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS ................................ ................................ ................................ .......... 63
10.1. Appendix 1: Regulatory , Ethical, a nd Study  Oversight Considerations ............... 63
10.1.1. Regulatory  and Ethical Considerations ................................ .................... 63
10.1.2. Financial Disclosure ................................ ................................ ................. 64
10.1.3. I nformed Consent Process ................................ ................................ ........ 64
10.1.4. Data Protection ................................ ................................ ......................... 65
10.1.5. Dissemination of Clinical Study  Data ................................ ...................... 66
10.1.6. Data Qualit y Assurance ................................ ................................ ............ 67
10.1.7. Source Documents ................................ ................................ .................... 68
10.1.8. Study  and Site Start and Closure ................................ .............................. 69
10.1.9. Publication Policy ................................ ................................ ..................... 69
10.1.10. Sponsor’s Qualified Medical Personnel ................................ ................. 70
10.2. Appendix 2 : Clinical Laboratory  Tests ................................ ................................ .71
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ................................ ................................ ......73
10.3.1. Definition of AE ................................ ................................ ....................... 73
10.3.2. Definition of SAE ................................ ................................ ..................... 74
10.3.3. Recording/Reporting and Follow up of AEs and/or SAEs ....................... 75
10.3.4. Reporting of SAEs ................................ ................................ .................... 78
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy  
Information ................................ ................................ ................................ ................ 80
10.4.1. Male Participant Reproductive Inclusion Criteria ................................ ....80
10.4.2. Female Participant Reproductive Inclusion Criteria ................................ .80
10.4.3. Woman of Childbearing Potential (WOCBP) ................................ .......... 80
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 710.4.4. Contraception Methods ................................ ................................ ............. 81
10.5. Appendix 5: Genetics ................................ ................................ ............................ 83
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -up Assessments 
and Study  Intervention Rechallenge Guidelines ................................ ....................... 84
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ................................ ...86
10.8. Appendix 8: Medical Device Adverse Events, Adverse Device Effects, 
Serious Adverse Events, and Device Deficiencies: Definition and Procedures 
for Recordin g, Evaluating, Follow -up, and Reporting ................................ .............. [ADDRESS_18783] ................................ ................................ ................................ ...88
10.8.3. Definition of Device Deficiency ................................ ............................... 89
10.8.4. Recording/Reporting and Follow -up of AEs and/or SAEs and 
Device Deficiencies ................................ ................................ ......................... 89
10.8.5. Reporting of SAEs ................................ ................................ .................... 91
10.8.6. Reporting of SADEs ................................ ................................ ................. 92
10.9. Appendix 9: Country -specific Requirements ................................ ........................ 93
10.10. Appendix 10: Evaluation of Participants with Decreased Platelet Count ........... 94
10.11. Appendix 11: Evaluation of Participants with Worsening Renal Function ........ 95
10.12. Appendix 12: Management of Elevated AST or AL T................................ ........ 96
10.13. Appendix 13: Alternative Measures During Public Emergencies ....................... 97
10.13.1. Eligibility ................................ ................................ ................................ 97
10.13.2. Home Health Visits ................................ ................................ ................. 97
10.13.3. Telehealth Visits ................................ ................................ ..................... 98
10.13.4. Alternative Facilities for Safet y Assessments ................................ ........ 98
10.13.5. Study  Intervention ................................ ................................ .................. 99
10.13.6. Adverse Events and Serious Adverse Events ................................ .......100
10.13.7. Efficacy  Assessments ................................ ................................ ........... 100
10.13.8. I ndependent Oversight Committees ................................ ..................... 100
10.14. Appendix 14: Abbreviations ................................ ................................ ............. [ADDRESS_18784] OF FIGURES
Figure 1. Study  Schematic ................................ ................................ ....................... 14
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 91.PROTOCOL SUMMARY
1.1.Synopsis
Protocol Title: APhase 2b Randomized, Double -Blind, Placebo -Controlled, Parallel 
Group, Dose -Ranging Study to Assess the Efficacy, Safety, and Tolerability of 
Vupanorsen (PF -[ZIP_CODE] 557) in Statin -Treated Participants with Dyslipi[INVESTIGATOR_19922]: A Phase 2b Dose -Ranging Study with Vupanorsen (PF -07285557) 
(TRANSLATE -TIMI 70)
Rationale:
This multicenter, Phase 2b, double -blind, placebo -controlled, parallel group study  is being 
conducted in ternationally to provide data on efficacy , safet y, tolerability , and 
pharmacokinetics ( PK)of PF -07285557 (hereafter, vupanorsen) administered subcutaneousl y 
(SC)at various doses and regimens in participants with dy slipi[INVESTIGATOR_035], defined in this study  as 
participants with elevated non -HDL -C and TG who are receiving a stable dose of a statin. 
This study  is intended to enable selection of a dose(s) for future development of vupanorsen 
for cardiovascular ( CV)risk reduction and hy pertrigl ycerid emia.
This study is also known as TaRgeting ANGPTL3 with an aNtiSense oLigonucleotide in 
AdulTs with dy slipid Emia (TRANSLATE -TIMI 70).
Objectives and Endpoints
Objectives Endpoints
Primary: Primary: 
To estimate the effects of multiple dose levels and 
regimens of vupanorsen compared to placebo on non -
HDL -C.Percent change from baseline in non -HDL -C at 
Week 24
Secondary: Secondary: 
To estimate the effects of multiple dose levels and 
regimens of vupanorsen compared to placebo on lipid 
parameters including TG, ApoB, and LDL -C.
To estimate the effects of multiple dose levels and 
regimens of vupanorsen compared to placebo on 
ANGPTL3.Percent change from baseline in TG, ApoB, and LDL -
C at Week 16 and W eek 24
Percent change from baseline in non -HDL -C at 
Week 16
Percent change from baseline in ANGPTL3 at 
Week 16 and Week 24
Safety: Safety:
To evaluate the safety, tolerability, and 
immunogenicity of multiple dose levels and regimens 
of vupanorsen.
To evaluate the effect of multiple dose levels and 
regimens of vupanorsen on HFF. Incidence of treatment -emergent SAEs and AEs 
throughout the study
Incidence of AESI 
Categorical summaries of clinical laboratory 
abnormalities
UACR
ADA
Change from baseline in AST, ALT, platelet counts, 
and eGFR
Change and percent change from baseline in HFF 
(assessed by [CONTACT_9268] -PDFF) at Week 24
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 10Objectives Endpoints
Tertiary/Exploratory: Tertiary/Exploratory:
To estimate the effects of multiple dose levels and 
regimens of vupanorsen compared to placebo on total 
cholesterol, HDL -C, VLDL -C, Lp(a), FFA, ApoB -48, 
ApoB -100, ApoC -III, and ApoA -I.
To estimate the effects of multiple dose levels and 
regimens of vupanorsen compared to placebo on 
hsCRP.
To evaluate the PK of vupanorsen .Percent change from baseline at Week 24 in total 
cholesterol, HDL -C, VLDL -C, Lp(a), FFA, ApoB -48, 
ApoB -100, ApoC -III, and ApoA -I
Percent change from baseline in hsCRP at Week 24
Plasma concentrations of vupanorsen at Weeks 12, 16 
and 24
Estimands: The primary estimand of t his study  will follow the hy pothetical estimand 
approach to estimate the effect of treatment under the hy pothetical condition that all 
participants maintained their randomized treatment through Week 24. This estimand is meant 
to estimate the pharmacologica l effect of the drug when taken as directed. It includes the 
following 4 attributes:
Population: Participants with dy slipi[INVESTIGATOR_19923] a statin who meet the 
inclusion/exclusion criteria .
Variable: The percent change from baseline in non -HDL -C at Week 24.
Intercurrent event: All off -treatment data (ie, occurring at least 1 dosing interval after 
discontinuation of treatment) or data collected post treatment of severe 
hypertrigly ceridemia (ie, change in statin dose or addition of TG lowering therapy ), if 
collected, will be excluded from anal ysis.
Population -level summary: Difference of variable means between vupanorsen and 
placebo.
Overall Design
This is a multicenter, randomized, double -blind, placebo -controlled, dose -ranging, 8 -arm 
parallel -group stud y in adults ≥40 y ears of age with dy slipi[INVESTIGATOR_19924] a stable dose of 
a statin (with or without ezetimibe). Following the Screening Period to confirm eligibility , a 
total of approximately  260 participants will be rand omized in the study  to receive SC doses 
of vupanorsen or placebo administered Q2W or Q4W for the purpose of assessing efficacy , 
safet y, and tolerability of vupanorsen . The total duration of treatment in the study  is 24 
weeks with an additional 12 -week safe ty follow -up period.
The sponsor, along with academic leadership of the study  (TIMI Study  Group), will monitor 
the proportion of participants enrolled according to statin intensity  to ensure that an adequate 
number of participants on high intensity  statin are enrolled. High in tensity  statin use is 
defined as atorvastatin (40 mg or 80 mg per day ) or rosuvastatin (20 mg or 40 mg per day ). 
All other statin regimens are considered low or moderate intensit y. Approximately  40% or 
more of participants enrolled should be on high intens ity statin therap y, and enrollment of 
participants using low/moderate intensit y statin may be capped.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 11Vupanorsen dosing will be accomplished by  [CONTACT_17814] 1 or 2 prefilled sy ringes of 
either 60 mg or 80 mg strength according to required total dose. Placebo will be provided as 
a prefilled s yringe and will be administered as either 1 or 2 s yringes. See Table S1 for the 
dosing plan. 
Table S 1.Dosing Plan
Treatm ent Arm Total Monthly 
DoseInjection Regimen Number of 
Participants
Placebo 0 mg Single or double injection Q2W or Q4W 40
80 mg Q4W 80 mg Single injection Q4W 20
60 mg Q2W 120 mg Single injection Q2W 20
120 mg Q4W 120 mg Double injection Q4W 20
80 mg Q2W 160 mg Single injection Q2W 40
160 mg Q4W 160 mg Double injection Q4W 40
120 mg Q2W 240 mg Double injection Q2W 40
160 mg Q2W  320 mg Double injection Q2W 40
Treatment arm will be capped at [ADDRESS_18785] participants or caregivers how to perform the 
SC injection, and participants (or caregivers) willing to perform the injection will be assessed 
for ability  to inject correctly . Sites will determine whether a participant or caregiver is 
willing and able to correctly  perform the SC injection. Participants receiving monthly  
injections will self -administer study  intervention (or be injected b y their caregiver) on -site.  
Participants receiving Q2W injections will self -administer study  intervention (or be injected 
by [CONTACT_19963]) on -site when stud y visits coincide with the dosing interval (Weeks 2 
and6, and at designated monthly  visits). Th e study  site will dispense study intervention for 
the participant or caregiver to inject at home for the doses that do not coincide with a study  
visit (Weeks 10, 14, 18, and 22). 
Safety  clinical laboratory parameters and AEs, including injection site reac tions, will be 
monitored throughout the study . HFF will be assessed at Screening and Week 24 using 
MRI -PDFF, and blood samples will be collected for lipi[INVESTIGATOR_805], lipoproteins, PK, PD, hsCRP, and 
anti-vupanorsen antibodies at various time points during the stud yaccording to the SoA. 
MRI -PDFF will be read by  a central reviewer, blinded to treatment group, lipid levels, and 
other clinical variables, such as concentrations of hepatic enz ymes.
This study  will include an E -DMC who will be responsible for ongoing, unblinded 
monitoring of efficacy  and the safet y of participants in the study  according to the E -DMC 
charter. 
Since administration of 160 mg Q2W (total monthly  dose of 320 mg) has not been studied 
previously , enrollm ent in this arm will be capped after [ADDRESS_18786] approximately  16 weeks after 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 1250% of the planned participants (ie, approximately 1 10participants), with the exception of 
the [ADDRESS_18787] -dose follow -up visit.
Number of Participant s:
Approximately  260 participants will be randoml y assigned/enrolled to study intervention. 
Note: "Enrolled" means a participant's, or his or her legally  authorized representative’s, 
agreement to pa rticipate in a clinical study  following completion of the informed consent 
process. Potential participants who are screened for the purpose of determining eligibility  for 
the study , but do not participate in the study , are not considered enrolled.
Interv ention Groups and Duration:
Participants will be randomized to receive blinded placebo or 1 of 7 blinded vupanorsen
treatment regimens for 24 weeks. 
Data Monitoring Committee: Yes
Statistical Methods:
Assuming a common standard deviation of 17.5% (observed in the Month 6 data of the 
Phase 2a proof -of-concept and dose -ranging study ) for the percent change from baseline in 
non-HDL -C at Week 24 and a treatment discontinuation rate of 15%, 20 participants p er arm 
will correspond to a 95% CI  of point estimate ±11.76% for the difference of treatment effect 
(versus placebo). These parameters correspond to a power of 91.5% using a 2-sided alpha of
0.05,to detect a difference of -20%, without adjustment for mul tiple comparison to placebo.
A permutation block schedule will be used in enrollment within each arm, including 
vupanorsen and matching placebo. If enrollment is stopped for the 160 mg Q2W arm, the 
corresponding matching placebo enrollment will also be sto pped.
The primary  statistical method of Mixed Model Repeated Measurements ( MMRM )will 
apply  to continuous endpoints.
Statistical efficacy  comparison will be made between each dose of vupanorsen and placebo 
for primary  and secondary  endpoints, respectivel y. Placebo -adjusted LS mean difference, 
95% CI , and p -value will be presented. Since this study  is exploratory  in natur e, no 
multiplicity  adjustment of endpoints nor adjustment of multiple comparison to placebo will 
be made. Sensitivity  analy ses/supplementary  analy ses are defined in the SAP. Since the visit 
after Week 24 is considered safet y follow -up, the statistical anal yses at those visits will be 
presented but the p -value will be treated onl y as nominal.
In addition, a Bay esian E max dose-response model will be estimated to illustrate the expected 
relationship between doses and their corresponding (percent) change from b aseline at 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 13Week 24 for primary  and key  secondary  endpoints, respectivel y. For each endpoint, 95% CI  
at each studied dose level will also be constructed.
In addition to analy ses, summary  statistics, listings, and figures will be provided.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 141.2.Schema
Figu re 1.Study Schematic

Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 151.3.Schedule of Activities (SoA)
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to c onduct 
evaluati ons or assessments required to protect the well -being of the participant. In the event of a health care crisis, pandemic, or other 
emergency , some of the assessments may  be performed via home health visits or other way s after discussion with the sponsor. See 
Appendix 13 for alternative measures that may  be allowed during a public emergency , such as COVID -19.
Visit Identifiera
Abbreviations used in this table 
may be found in Appendix 1 4.Screeningb
(Days -28 to -1)Day 
1Day 
8Day 
15Day 
29Day 
43Day 
57Day 
85Day 113
Interim 
Analysis Time 
PointDay 
141Day
169Follow -up
(+[ADDRESS_18788] dose)e,fEarly Termination/
Discontinuationg
Visit 
1c,dVisit 
2Visit 
3
Week -4 to -1 0 1 2 4 6 8 12 16 20 24 32 or 34
Month -1 1 2 3 4 5 6 8
Visit Window (Days) ±1 ±1 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±7
Informed consent X
Medical history X
Inclusion/Exclusion Criteria X X
Physical examination X
Vital signs ( seated blood 
pressure and pulse rate)X X X X X
Weight X X X X
Height X
Provide contact [CONTACT_19964] X X XiX X X X X X X X X X
Blood chemistry X X XiX X X X X X X X X X
Lipid panel and ApoBjX X X X X X X X X X
Extended lipoprotein 
panel and FFAkX X X
ANGPTL3lX X X X X X X X
HbA 1c X X X X X
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 16Visit Identifiera
Abbreviations used in this table 
may be found in Appendix 1 4.Screeningb
(Days -28 to -1)Day 
1Day 
8Day 
15Day 
29Day 
43Day 
57Day 
85Day 113
Interim 
Analysis Time 
PointDay 
141Day
169Follow -up
(+[ADDRESS_18789] dose)e,fEarly Termination/
Discontinuationg
Visit 
1c,dVisit 
2Visit 
3
Week -4 to -1 0 1 2 4 6 8 12 16 20 24 32 or 34
Month -1 1 2 3 4 5 6 8
Visit Window (Days) ±1 ±1 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±7
Urinalysis X XXiX X X X X X X X X X
Urine albumin to 
creatinine ratioX XXiX X X X X X X X X X
FSH (w omen, if 
applicable)X
Pregnancy testmX X X X X X X X X X X X
Plasma PK XnXnXoX
hsCRP X X X
PT, aPTT, INR X XiX X X X X X X X X X
Anti-vupanorsen
antibodies (ADA)XpXpXpXpXpX X
Banked Biospecimen 
Samples Prep B1.5 
(plasma), B2.5 (serum), 
M4 (urine)qX XoX
[COMPANY_007] Prep D1 Banked 
Biospecimen(s)qX
Contraception check X X X X X X X X X X X X
12-Lead ECG X XoX
MRI -PDFFrX Xo,sX
Randomization X
IRT interaction X X X XtX XtX X X X X
Study intervention
Placebo -injection 
instruction and trainingX
Q2Wu,vX XiX X X X X X
Q4WuX XiX X X X
Revie w diary to assess 
treatment complianceX X X X X
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 17Visit Identifiera
Abbreviations used in this table 
may be found in Appendix 1 4.Screeningb
(Days -28 to -1)Day 
1Day 
8Day 
15Day 
29Day 
43Day 
57Day 
85Day 113
Interim 
Analysis Time 
PointDay 
141Day
169Follow -up
(+[ADDRESS_18790] dose)e,fEarly Termination/
Discontinuationg
Visit 
1c,dVisit 
2Visit 
3
Week -4 to -1 0 1 2 4 6 8 12 16 20 24 32 or 34
Month -1 1 2 3 4 5 6 8
Visit Window (Days) ±1 ±1 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±7
Prior and concomitant 
treatment(s)X X X X X X X X X X X X X
Serious and nonserious 
adverse event monitoringX X X X X X X X X X X X X X X
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 18Visit Identifiera
Abbreviations used in this table 
may be found in Appendix 1 4.Screeningb
(Days -28 to -1)Day 
1Day 
8Day 
15Day 
29Day 
43Day 
57Day 
85Day 113
Interim 
Analysis Time 
PointDay 
141Day
169Follow -up
(+[ADDRESS_18791] dose)e,fEarly Termination/
Discontinuationg
Visit 
1c,dVisit 
2Visit 
3
Week -4 to -1 0 1 2 4 6 8 12 16 20 24 32 or 34
Month -1 1 2 3 4 5 6 8
Visit Window (Days) ±1 ±1 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±7
a. Day relative to start of study intervention (Day 1).
b. Screening Period is a maximum of 28 days .Complete all inclusion/exclusion procedures and assessments denoted at Screening Visit 1; placebo injection training may be 
performed at Screening Visit [ADDRESS_18792] dose: Week 32 for participants assigned to Q4W regimen or Week 34 for participants assigned to Q2W regimen.
f. For participants who discontinue the study after Week 24, perform Follow -up procedures; do not perform Early Termination/Discontinuation procedures.
g. For participants who discontinue study intervention or discontinue the study prior to Week 24, the procedures should be performed. Early Termination/Discontinuation 
procedures to be performed as soon as practically possible after decision to stop study intervention but participants should stay in study with continuation of scheduled visits 
unless participant withdraws consent from further study participation.
h. Diary to be dispensed only to participants assigned to Q2W regimen.
i. Laboratory results from Week 1 visit should be reviewed by [CONTACT_19965] 2 dosing for participants dosin g Q2W and prior to Week 4 dosing for participants 
dosing Q4W.
j. Lipid panel and ApoB should be obtained with participants in a fasted state ( Section 5.3.2 ). Lipid panel includes non -HDL -C, TG, direct LDL -C, total cholesterol, HDL -C, 
direct VLDL -C.
k. Extended lipoprotein panel and FFA should be obtained with participants in a fasted state ( Section 5.3.2 ). Extended lipoprotein panel includes Lp(a), ApoB -48, ApoB -100, 
ApoC -III, ApoA -I.
l. ANGPTL3 should be obtained with participants in a fasted state ( Section 5.3.2 and Section 8.6).
m. For WOCBP. Perform serum pregnancy test at Screening. Perform urine pregnancy test p rior to dosing at visits on Week 0, Week 2 through Week 24, Follow -up, and Early 
Termination/Discontinuation (if applicable).
n. PK sample collected with participants in a fasted state ( Section 5.3.2 ) at trough (prior to dosing with study intervention) and 2 to 4 hours after administration.
o. Do not perform assessment/procedure at Day 169 for participants who continued scheduled visits after stoppi[INVESTIGATOR_19925]/Discontinuation assessments/procedures.
p. ADA samples to be collected prior to dosing with study intervention.
q. If not collected on the designated collection day, collect at the next available time point when biosp ecimens are being collected in conjunction with a participant visit. 
r. Assessment to be performed, following ≥4-hour fast, at site (as part of site visit) or separate visit(s) to Imaging facility (see Section 5.3.2 ).
s. Attempts to be made to stay within ±2 -hour window of the time when MRI -PDFF was performed at Screening.
t. Dispense study intervention only to participants assigned to Q2W regimen for home dosi ng.
u. For each site visit, perform all indicated procedures and assessments prior to participant self -injection (or caregiver administering injection).
v. Dosing at home for participants in the Q2W regimens will occur on Weeks 10, 14, 18, and 22; the window for each scheduled dosing day is ±2 days. Study intervention will 
be dispensed at the prior visit for these doses. 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 192.INTRODUCTION
ANGPTL 3 is a protein primarily  synthesized and secreted b y the liver and is a member of the 
angiopoietin -like family  of proteins. ANGPTL3 is a genetically -validated target of lipid 
metabolism and CV disease.1
PF-07285557 (hereafter, vupanorsen) is a second -generation 2’ -MOE ASO targeting hepatic 
ANGPTL 3 mRNA. Vupanorsen is planned to be develope d for CV risk reduction and for TG 
lowering in patients with severe h ypertrigl yceridemia.
Vupanorsen is a s ynthetic oligomer of 20 nucleotides that are connected sequentially  by 
[CONTACT_19966] (mixed backbone design) and coval ently 
bound to GalNAc, which binds with high affinit y to the ASGPR on hepatocytes, increasing 
hepatocy te delivery  and potency . The mixed backbone design reduces the total number of 
phosphorothioate linkages in the MOE -modified regions, which reduces non -specific 
interactions with proteins and further enhances potency  of GalNAc -conjugated ASOs.
Phase [ADDRESS_18793] demonstrated marked 
reductions in ANGPTL3 protein and reductions in TG, VLDL -C, and non -HDL -C. The 
favorable lipid changes along with human genetic data indicate that inhibition of ANGPTL3 
with vupanorsen could represent a novel approach to decrease CV disease risk and reduce 
TG in participants with hypertrigly ceridemia.
2.1.Study Rationale
This multicenter, Phase 2b, double -blind, placebo -controlled, parallel group study  is being 
conducted in ternationally to provide data on efficacy , safet y, tolerability , and PK of 
vupanorsen administered SC at various doses and regimens in participants with dy slipi[INVESTIGATOR_035], 
defined in this study  as participants with elevated non -HDL -C and TG who are receiving a 
stable dose of a statin. This study  is intended to enable selection of a dose(s) for future 
development of vupanorsen for CV risk reduction and hy pertrigl yceridemia.
This study  is also known as TaRgeting ANGPTL3 with an aNtiSense oLigonucleotide in 
AdulTs with dy slipi[INVESTIGATOR_19926] (TRANSLATE -TIMI 70). 
2.2.Background
2.2.1. Atherosclerotic Cardiovascular Disease
Individuals with established ASCVD, a prior history  of ischemic events, or multiple risk 
factors for atherothrombosis are at high risk for future ischemic events and CV death.2Both 
epi[INVESTIGATOR_19927] a strong and 
linear relationship between levels of LDL -C and CV events. Earl y intensive statin therap y to 
lower LDL -C has become a foundation of treatment for patients with ASCVD.3However, 
even with guideline -based optimal L DL-C lowering treatment, patients with ASCVD remain 
at high risk for CV death and recurrent is chemic events.4
A growing bod y of clinical and epi[INVESTIGATOR_19928] -HDL -C is a better 
predictor of CV risk than L DL-C alone.5,6Non-HDL -C encompasses the cholesterol content 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 20of all the atherogenic ApoB -containing lipoproteins including LD L, VLD L, ID L, Lp(a), 
chylomicrons, and chy lomicron remnants. Thus, non -HDL -C provides a simple way  to assess 
the total amount of atherogenic lipoproteins containing ApoB. Collectively, IDL, VLDL, and 
chylomicron remnants are termed TG -rich lipoproteins. El evated plasma TG is a marker for 
elevated TG -rich lipoproteins. Several lines of evidence have established a likely  causal role 
for TG -rich lipoproteins in atherogenesis, mediated by  [CONTACT_19967].7TG-rich lipoprotei ns are strong independent predictors of ASCVD and 
all-cause mortality  in epi[INVESTIGATOR_19929].7Genetic studies of various factors influencing the function of lipoprotein 
lipase, a key  enzyme that degrades TG -rich lipoproteins in plasma and regulates the delivery  
of fatt y acids to adipose tissue and muscle, provide evidence that TG -rich lipoproteins are a 
causal fac tor in ASCVD.5
In randomized controlled trials, reduction in TG (a surrogate of TG -rich lipoproteins) is 
associated with a lower risk of major vascular events, even after adjustment for LDL -C 
lowering, although the effect on vascular events is less than that for LDL -C or non -HDL -C 
reduction.8Most previous non -statin trials of existing therapi[INVESTIGATOR_19930] (fibrates, niacin, 
omega -3 fatty  acids) have had modest reduc tions in non -HDL -C and TG and have been 
underpowered to detect reductions in CV events.[ADDRESS_18794] effects on TG (5% to 15%). Other therapi[INVESTIGATOR_19931]. 
High doses of icosapent ethy l also has modest effects on TG (me dian reduction of 
approximately  20%) but reduced CV risk by  25%, suggesting effects on CV outcomes 
beyond lowering TG.[ADDRESS_18795] been defined: moderate hy pertrigl yceridemia 
(TG 150 -499 mg/dL) and severe h ypertrigl yceridemia ( TG ≥500 mg/dL). Moderate 
hypertrigly ceridemia is commonly  associated with obesity , T2DM, and insulin resistance, 
and the excess TG are primarily  carried in VLDL.3Patien ts with severe h ypertrigly ceridemia 
have an excess of ch ylomicrons (chy lomicronemia) in addition to an excess of TG -rich 
lipoproteins.  
In addition to increased ASCVD risk, hy pertriglyceridemia is a well -established cause of 
acute pancreatitis. The pancre atitis risk is highest in familial chy lomicronemia sy ndrome, but 
there is evidence to indicate that pancreatitis risk is increased even in mild or moderate 
hypertrigly ceridemia and the risk increases in a dose -dependent manner as TG levels 
increase.10
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 21Treatment of severe h ypertrigl yceridemia has 2 aspects: lowering lipid levels to decrease 
ASCVD risk and the more acute goal of reducing elevated TG to reduce risk of acute 
pancreatitis. L DL-C lowering treatments have only  moderate effects on TG, but lower
ASCVD risk in patients with hy pertrigl yceridemia or mixed dy slipi[INVESTIGATOR_035]. There is a need for 
therapi[INVESTIGATOR_19932].
2.2.3. Rationale for ANGPTL3 Inhibition
ANGPTL [ADDRESS_18796] shown that ANGPTL 3 
deficiency  is associated with a reduced risk of coronary  artery  disease.15
2.2.4. Clinical Overview
One Phase 1 single -and multiple -ascending dose study  (CS1) (hereafter, Phase 1) in healthy  
volunteers, 1 Phase 2a proof -of-concept and dose -ranging stud y (CS2) (hereafter, Phase 2a), 
and 2 small, open -label, single -arm, proof -of-concept studies (in participants with Familial 
Chylomicronemia S yndrome and Familial Partial Lipod ystroph y) have been conducted. 
Refer to the IB for more details on these studies, including clinical efficacy and safet y results 
forthe Phase 2a study .
Clinical PK results for the Phase 2a stud y are presented in Section [IP_ADDRESS] .
[IP_ADDRESS]. Clinical Pharmacokinetics
Concentrations of total full -length oligo nucleotide in plasma, including the parent compound 
vupanorsen , its full -length oligonucleotide metabolites with 1, 2, and/or [ADDRESS_18797] on C max and AUC, but increased plasma trough 
concentrations based on preliminary  anal ysis.   
2.3.Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of vupanorsen may be found in the IB, which is the SRSD for this study . 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 232.3.1. Risk Assessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Study Intervention(s) [vupanorsen ] 
Decreased platelet counts, elevated 
transaminases, and decreased renal 
function are potential risks 
associated with vupanorsen .The potential risks are based on 
reports of thrombocytopenia, 
elevated liver enzymes, and 
decreases in renal function in 
clinica l and non -clinical studies of 
other non -GalNAc conjugated 
ASOs.16,17
Thrombocytopenia has not been 
observed in non -clinical and 
clinical studies of vupanorsen (see 
IB for non -clinical and clinical 
study results).
No vupanorsen -associated severe 
decline in platelet counts were 
reported in the Phase 1 or 2a study 
(see IB).
The potential risk of elevated 
transaminases is based on the 
results of the Phase 2a study where 
increases in mean ALT that 
appeared dose dependent were 
observed in all vupanorsen
treatmen t groups, and mild isolated 
transaminase increases that 
exceeded the 3 times the upper 
limit of normal occurred in 
2participants at the 20 mg QW 
dose; the transaminase increases 
were not associated with an Eligibility criteria will ensure the appropriate participants enter the study (see 
Exclusion Criterion 4).  
AEs and clinical laboratories will be obtaine d and monitored throughout the study 
(see SoA). Also, the protocol includes monitoring and stoppi[INVESTIGATOR_19933], elevated transaminases, and decrease in eGFR (see
Section 7.1). Instructions for managing potential liver injury are provided (see 
Appendix 6 ).
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 24Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
increase in bilirubin or 
liver-related symptoms ( see IB).  
Injection site reactions are a 
potential risk of vupan orsen .Injection site AEs were the most 
common side effects observed 
following SC administration of 
unconjugated 2’ -MOE ASOs and 
were dose dependent.[ADDRESS_18798] been 
observed in the Phase 1 and Phase 
2a (see IB) studies of vupanorsen
and hav e generally been mild.Injection site instructions to minimize injection site AEs will be provided to the 
participant or caregiver (if applicable).
AEs will be monitored on an ongoing basis throughout the study (see SoA). Also, 
the protocol requires discontinuation of dosing if a severe injection site reaction 
occurs (see Section 7.1.2 ).
Study Procedures
MRI -PDFF will be used to assess 
liver fat.MRI -PDFF can cause 
claustrophobia and also is 
contra -indicated in individuals 
with certain medical devices or 
other internal metallic objects.Eligibility criteria will ensure the appropriate participants enter the study (see 
Exclusion Criterion 19).
Participants will self -inject (or 
caregivers will inject) study 
intervention.Participants or caregivers may 
perform the injection incorrectly.
Participants may be uncomfortable 
self-injecting.Sites will train participants or caregivers to perform the injection.
During Screening, partic ipants or caregivers will inject placebo in order to 
determine whether study intervention can be correctly administered.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 252.3.2. Benefit Assessment
Treatment with vupanorsen may lower non -HDL -C, TG, and other lipi[INVESTIGATOR_805]/lipoproteins 
associated w ith ASCVD and ischemic events. Participants will be followed closely  by a 
physician for approximately  32 weeks (Q4W regimen) or 34 weeks (Q2W regimen) and will 
have measurements of lipi[INVESTIGATOR_805], blood pressure, and other clinical laboratories throughout the 
study. Measurements of liver fat using MRI -PDFF may , after unblinding of the study , 
identify  elevated liver fat in some participants who were unaware that they had this condition 
and inform their post -study  management by  [CONTACT_19968]. Fin ally, 
participants will be contributing to the development of a potential therap y to reduce risk of 
CV events and to treat individuals with elevated TG.
2.3.3. Overall Benefit/Risk Conclusion
Taking into account the measures taken to minimize risk to participants participating in this 
study , the potential risks identified in association with vupanorsen and study  procedures are 
justified by  [CONTACT_19969] h ypertrigl yceridemia.
3.OBJECTIVES AND ENDPO INTS
Objectives Endpoints
Primary: Primary: 
To estimate the effects of multiple dose levels and 
regimens of vupanorsen compared to placebo on non -
HDL -C.Percent change from baseline in non -HDL -C at 
Week 24
Secondary: Secondary: 
To estimate the effects of multiple dose levels and 
regimens of vupanorsen compared to placebo on lipid 
parameters including TG, ApoB, and LDL -C.
To estimate the effects of multiple dose levels and 
regimens of vupanorsen compared to placebo on 
ANGPTL3.Percent change from baseline in TG, ApoB, and 
LDL -C at Week 16 and Week 24
Percent change from baseline in non -HDL -C at 
Week 16
Percent change from baseline in ANGPTL3 at 
Week 16 and Week 24
Safety: Safety:
To evaluate the safety, tolerability, and 
immunogenicity of multiple dose levels and regimens 
of vupanorsen .
To evaluate the effect of multiple dose levels and 
regimens of vupanorsen on HFF. Incidence of treatment -emergent SAEs and AEs 
throughout the study
Incidence of AESI 
Categorical summaries of clinical laboratory 
abnormalities
UACR
ADA
Change from baseline in AST, ALT, platelet counts, 
and eGFR
Change and percent change from baseline in HFF 
(assessed by [CONTACT_9268] -PDFF) at Week 24
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 26Objectives Endpoints
Tertiary/Exploratory: Tertiary/Exploratory:
To estimate the effects of multiple dose levels and 
regimens of vupanorsen compared to placebo on total 
cholesterol, HDL -C, VLDL -C, Lp(a), FFA, ApoB -48, 
ApoB -100, ApoC -III, and ApoA -I.
To estimate the effects of multiple dose levels and 
regimens of vupanorsen compared to placebo on 
hsCRP.
To evaluate the PK of vupanorsen .Percen t change from baseline at Week 24 in total 
cholesterol, HDL -C, VLDL -C, Lp(a), FFA, ApoB -48, 
ApoB -100, ApoC -III, and ApoA -I
Percent change from baseline in hsCRP at Week 24
Plasma concentrations of vupanorsen at Weeks 12, 16, 
and 24
The primary  estimand of this study  will follow the hy pothetical estimand approach as 
described in Section 9.1.1 .
4.STUDY DESIGN
4.1.Overall Design
This is a multicenter , randomized, double -blind, placebo -controlled, dose -ranging, 8-arm 
parallel -group stud y in adults ≥40 years of age with dy slipi[INVESTIGATOR_19924] a stable dose of 
a statin (with or without ezetimibe) . Following the Screening Period to confirm eligibility , a 
total of approximately  260 participants will be randomized in the study  to receive SC doses 
of vupanorsen or placebo administered Q2W or Q4W for the purpose of assessing efficacy , 
safet y, and tolerab ility of vupanorsen . The total duration of treatment in the study  is 
24weeks with an additional 12 -week safet y follow -up period.
The sponsor, along with academic leadership of the study  (TIMI Study  Group), will monitor 
the proportion of participants enrol led according to statin intensity  to ensure that an adequate 
number of participants on high intensity  statin are enrolled. High intensity  statin use is 
defined as atorvastatin (40 mg or 80 mg per day ) or rosuvastatin (20 mg or 40 mg per day ). 
All other sta tin regimens are considered low or moderate intensit y. Approximately  40% or 
more of participants enrolled should be on high intensity  statin therap y, and enrollment of 
participants using low/moderate intensit y statin may be capped.
Vupanorsen dosing will b e accomplished by  [CONTACT_17814] 1 or 2 prefilled sy ringes of 
either 60 mg or 80 mg strength according to required total dose. Placebo will be provided as 
a prefilled s yringe and will be administered as either 1 or 2 s yringes. See Table 1 for the 
dosing plan. 
Table 1.Dosing Plan
Treatm ent Arm Total Monthly Dose Injection Regimen Number of 
Participants
Placebo 0  mg Single or double injection Q2W or Q4W 40
80 mg Q4W 80 mg Single injection Q4W 20
60 mg Q2W 120 mg Single injection Q2W 20
120 mg Q4W 120 mg Double injection Q4W 20
80 mg Q2W 160 mg Single injection Q2W 40
160 mg Q4W 160 mg Double injection Q4W 40
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 27Table 1.Dosing Plan
Treatm ent Arm Total Monthly Dose Injection Regimen Number of 
Participants
120 mg Q2W 240 mg Double injection Q2W 40
160 mg Q2W  320 mg Double injection Q2W 40
Treatment arm will be capped at [ADDRESS_18799] part icipants or caregivers how to perform the 
SC injection, and participants (or caregivers) willing to perform the injection will be assessed 
for ability  to inject correctly . Sites will determine whether a participant or caregiver is 
willing and able to corre ctly perform the SC injection. Participants receiving monthly  
injections will self -administer study  intervention (or be injected b y their caregiver) on -site. 
Participants receiving Q2W injections will self -administer study  intervention (or be injected 
by [CONTACT_19963]) on -site when stud y visits coincide with the dosing interval (Weeks 2 
and6, and at designated monthly  visits). The study  site will dispense study intervention for 
the participant or caregiver to inject at home for the doses that do not coin cide with a study  
visit (Weeks 10, 14, 18, and 22). 
Safety  clinical laboratory parameters and AEs, including injection site reactions, will be 
monitored throughout the study . HFF will be assessed at Screening and Week 24 using 
MRI -PDFF, and blood samples will be collected for lipi[INVESTIGATOR_805], lipoproteins, PK, PD, hsCRP, and 
anti-vupanorsen antibodies at various time points during the stud y according to the SoA. 
MRI -PDFF will be read by  a central reviewer, blinded to treat ment group, lipid levels, and 
other clinical variables, such as concentrations of hepatic enz ymes.
This study  will include an E -DMC who will be responsible for ongoing, unblinded 
monitoring of efficacy  and the safet y of participants in the study  according to the E -DMC 
charter (Section 9.6). 
Since administration of 160 mg Q2W (total monthly  dose of 320 mg) has not been studied 
previously , enrollment in this arm will be capped after [ADDRESS_18800] approximately  16 weeks after 
50% of the planned participants (ie, approximately 1 10participants), with exception of the 
[ADDRESS_18801] -dose follow -upvisit. 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 284.2.Scientific Rationale for Study Design
As reviewed in the IB, vupanorsen demonstrated significant reductions in TG and multiple 
lipid endpoints in the Phase 2a study  in participants with hy pertrigl yceridemia, NAFLD, and 
diabetes; however, the m aximal reduction in ANGPTL [ADDRESS_18802] dose of 
80mg Q4W in the study  was below the magnitude needed to observe maximal lipid lowering 
with this mechanism (ie, ≥75% ANGPTL3 reduction). From a safet y perspective, the 
numerical increases in li ver fat at 20 mg QW and 40 mg Q4W, along with the larger increase 
noted at 80 mg Q4W need to be further evaluated.
In the current study , the participant population is focused on those with elevated non -HDL -C 
and TG and are on a stable dose of a statin to d etermine the optimum dose for future 
development for h ypertrigl yceridemia and CV risk reduction. To further evaluate potential 
changes in liver fat accumulation, participants will complete MRI -PDFF at Screening and 
end of treatment (Week 24). In addition, banked biospecimens will be collected and stored 
for further anal yses which may , for example, provide greater understanding of vupanorsen .
Vupanorsen has an unlikely  risk of human teratogenicity /fetotoxicity .However, p articipants 
who are WOCBP must use an acceptable contraceptive method (see Appendix 4). The risk of 
vupanorsen causing damage to the DNA of sperm is considered low, and the risk of exposure 
to vupanorsen in a sexual partner of a male participant i n this study  via ejaculate is low ;
therefore ,no contraception (condom) use in male participants is required (see Appendix 4 ). 
The highest dose of vupanorsen planned for this study  would result in maternal systemic
exposure sviaseminal transfer well below (>5000 -fold) the exposure at the NOAEL for 
developmental toxicity  in nonclinical studies , including the conservative assumptions that an 
ASO ejaculate:serum ratio would be 1 and there is 100% up take by [CONTACT_3969] . 
4.3.Justification for Dose
A dose range of 80 mg Q4W to 160 mg Q2W will be evaluated for safet y and efficacy in this 
study . Based on simulation results using a preliminary  population PK/PD model developed 
from the combined data in the Phase 1 and Phase 2a studies, vupanorsen 80 mg Q4W is 
expected to be a minimal efficacious dose in non -HDL -C reduction (<8% probability  of 
achieving 35% mean reduction) and is included to bridge the data from previous studies. 
Vupanorsen 160 m g Q2W is expected to achieve >90% probabilit y of ≥35% mean reduction 
in non -HDL -C, which translates to a potential ≥20% CV relative risk reduction in CV events 
assuming non -HDL -C baseline of 125 mg/dL, in addition to maximizing ANGPTL [ADDRESS_18803] of  
maximum single dose administered at one time on the frequency  of AEs.
Single doses of vupanorsen up to 120 mg SC and multiple doses u p to 60 mg SC QW for 
6doses (total exposure of 360 mg) were safe and well -tolerated in healthy  volunteers in the 
Phase [ADDRESS_18804] multiple d ose administered (60 mg QW), 2 out of 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 296participants had elevations in liver enzy mes, with 1 participant exceeding >3 × ULN and 
without elevation in bilirubin. Both participants with AL T elevations in Phase [ADDRESS_18805] a stochastic finding. These observations included 
increase in HFF and small increases in mean ALT. I njection -site reactions will also be 
assessed in a larger sample size relative to earlier studies. This Phase 2b study  inclu des 
measures to mitigate these identified risks ( Section 2.3.1 ) and provide close oversight of 
participants. 
4.4.End of Study Definition
A participant is considered to have completed the study  if he/she has completed all phases of 
the study  including follow -up visit.
The end of the stud y is defined as the date of the last visit of the last participant in the study.
5.STUDY POPULATION
This study  can fulfill its obj ectives only  if appropriate participants are enrolled. The 
following eligibility  criteria are designed to select participants for whom participation in the 
study  is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol. 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1.Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex:
1.Male or female participants aged ≥40 y ears at Screening.
Refer to Appendix 4 for male and female reproductive inclusion criteria 
(Section 10.4.1 , Section 10.4.2 ,and Section 10.4.3 ) and for contraceptive 
requirements for female participants ( Section 10.4.4 ).
Type of Participant and Disease Characteristics:
2.Fasting non -HDL -C at Screening ≥100 mg/dL.
3.Fasting TG at Screening of 150 to 500 mg/dL, inclusive, which may  be repeated once if 
deemed necessary .
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18806] 1 month before Screening and 
plan to remain on the same medication and dose for the duration of the study . 
Weight:
5.Body weight ≥50 kg and ≤136 kg at Screening.
Informed Consent:
6.Capabl e of giving signed informed consent as described in Appendix 1 , which includes 
compliance with the requirements and restrictions listed in the I CD and in this protocol.
5.2.Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Participant has active liver disease (other than NAFLD or NASH, which are permitted), 
including chronic active hepatitis B or C or primary  biliary  cirrhosis.
2.Uncontrolled h ypertension (systolic blood pressure >180 mmHg or diastolic blood 
pressure >100 mmHg). Note: participants who are on an anti -hypertensive medication to 
treat h ypertension should be on a stable dose at least [ADDRESS_18807], if 
deemed necessary :
HbA 1c≥9.5%
eGFR <30 mL/min/1.73 m2(as determined b y the CKD -Epi [INVESTIGATOR_10908])
ALT or AST >2 × ULN
Total bilirubin ≥1.5 × ULN; participants with a history  of Gilbert’s s yndrome may 
have a direct bilirubin measured and would be eligible for this study  provided the 
direct bilirubin is ≤ULN
Platelet count <LLN
5.History  of clinically  significant acute cardiac event within 3 months before Screening 
(includes ischemic stroke, transient ischemic attack, my ocardial infarction, 
revascularization procedures, hospi[INVESTIGATOR_19934]).
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 316.Presence of [LOCATION_001] Heart Association Functional Classification IV heart failure 
symptoms at Screening.
7.Malignan cy within 5 y ears, except for basal or squamous cell carcinoma of the skin or 
carcinoma in situ of the cervix that has been successfully  treated.
8.Current history  of alcoholism or drug addiction according to Diagnostic and Statistical 
Manual of Mental Disor ders IV criteria within 12 months prior to Screening. Use of any  
recreational drugs within 12 months prior to Screening. 
9.Other medical or psy chiatric condition including recent (within the past y ear) or active 
suicidal ideation/behavior or laboratory  abno rmality  that may  increase the risk of study  
participation or, in the investigator’s judgment, make the participant inappropriate for the 
study .
Prior/Concomitant Therapy:
10.Prior treatment at an y time with vupanorsen .
11.Prior treatment with an y oligonucleoti de (including small interfering ribonucleic acid) 
within 6 months of Screening or prior treatment with inclisiran within 12 months of 
Screening.
12.Use of TG lowering medication (eg, Vascepa [icosapent eth yl]), non -prescription dietary  
supplements (eg, fish o il)or other cholesterol lowering medication (eg, fibric acid 
derivatives, niacin, PCSK9 inhibitors, bile acid sequestrants, bempedoic acid) [ADDRESS_18808] thrombin inhibitors, Factor Xa inhibitors ,
heparin s or heparinoids 30 day s prior to Screening.
Prior/Concurrent Clinical Study Experience:
14.Previous administration with an investigational drug within 30 days (or as determined by  
[CONTACT_19970]) or [ADDRESS_18809] dose of study  intervention used in 
this study  (whichever is longer).
Diagnostic Assessments:
15.Participant has a clinically significant ECG abnormality  during the Screening Period that 
requires further diagnostic evaluation or int ervention (eg, new, clinically  significant 
arrhythmia or a conduction disturbance).
Other Exclusions
16.Unstable weight (>5% shift in past month) or plan to start a diet for the purpose of 
significant weight loss.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 3217.Hypersensitivity  to the active substance or to any  of the excipi[INVESTIGATOR_19935].
18.Any major surgery , including bariatric surgery , within 3 months of Screening.
19.Participants with conditions contraindicated for MRI  procedures including pacemakers or 
aneury sm clips; the presence of MRI incompatible implanted devices; metallic foreign 
bodies; metal tattoos (including permanent make -up); or severe claustrophobia impacting 
the ability  to perform MRI . Participants who may require mild sedative or anxioly tic in 
order to complete the MRI  may  be enrolled.
20.Participants unwilling or unable to comply  with study  procedures, including follow -up, as 
specified b y this protocol, or unwillingness to cooperate fully with the Investigator.
21.Investigator site staff or [COMPANY_007] employ ees directl y involved in the conduct of the study , 
site staff otherwise supervised by  [CONTACT_093], and their respective family  members.
5.3.Lifestyle Considerations
5.3.1. Contraception 
Contraception is required only  for female participants of childbearing potential (see 
Appendix 4 Section 10.4.3 ). The investigator or his or her designee, in consultation with the 
participant, will confirm that the participant h as selected an appropriate method of 
contraception for the individual participant from the permitted list of contraception methods 
(see Appendix 4 Section 10.4.4 ) and will confirm that the participant has been instructed in 
its consistent and correct use. At time points indicated in the SoA, the investigator or 
designee will inform the participant of the need to use highl y effe ctive contraception 
consistently  and correctly  and document the conversation and the participant’s affirmation in 
the participant’s chart (participants need to affirm their consistent and correct use of at least 
1of the selected methods of contraception). In addition, the investigator or designee will 
instruct the participant to call immediately  if the selected contraception method is 
discontinued or if pregnancy  is known or suspected in the participant or partner.
5.3.2. Dietary Restrictions and Fasting
Particip ants should maintain their usual diet and exercise regimen throughout the study .
Participants should abstain from all food and drink (except water) for ≥10 hours prior to 
Screening Visit 1 and visits at Weeks 0, 4, 8, 12, 16, 20, 24, follow -up, and Earl y 
Termination/Discontinuation visit (if applicable) for testing of lipi[INVESTIGATOR_805], extended lipoprotein 
panel, FFA, ANGPTL3, hsCRP, or PK. Prior to the visit, the study  site should contact [CONTACT_19971]/her of the fasting requirement and specify  the t ime the participant 
should stop eating relative to the time of the visit. Participants are permitted to take 
concomitant medications (provided that they  can be taken in the fasting state), taken as 
prescribed with water, on the morning of a study  visit.
Participants must abstain from all food and drink (except water) for ≥4 hours prior to 
MRI -PDFF assessment.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 335.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to study  intervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet 
the CONSORT publishing requirements and to respond to queries from regulatory  
authorities. Minima l information includes demography , screen failure details, eligibility  
criteria, and an y SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened if they  failed for a documented treatable condition. I ndividuals may  not be 
rescreened if they  did not meet inclusion requirements for TG and non -HDL -C.  
5.5.Criteria for Temporarily Delaying Enrollment/Randomization/Study Intervention 
Administration
Not applicable.
6.STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, medical device(s), or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervent ion refers to vupanorsen orplacebo 
administered SC.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 346.1.Study Intervention(s) Administered
Study Intervention Vupanorsen Placebo
ARM Name 80 mg 
Q4W60 mg 
Q2W120 mg 
Q4W80 mg 
Q2W160 mg 
Q4W120 mg 
Q2W160 mg 
Q2WPlacebo
Type Drug Placebo
Dose Formulation 100 mg/mL 0 mg/mL
Unit Dose Strength(s) 60 mg/s yringe or 80 mg/syringe 0 mg/
syringe
Dosage Level(s) 80 mg 
Q4W60 mg 
Q2W120 mg 
Q4W80 mg 
Q2W160 mg 
Q4W120 mg 
Q2W160 mg 
Q2W0 mg Q2W 
or Q4W
Route of 
AdministrationSC SC
Use Experimental Placebo
IMP or NIMP IMP IMP
Sourcing Prefilled sy ringes will be provided centrally by [CONTACT_456]. See IP manual. 
Packaging and 
LabelingStudy  intervention will be provided in masked, prefilled sy ringes. Each prefilled sy ringe will be labeled 
as required per country  requirement.
Current/Former 
Name [CONTACT_20029]-[ADDRESS_18810] participants (or caregivers) how to perform 
the SC injection and proper sterile technique. Participants (or caregivers) will be dispensed a 
prefilled s yringe of open -label placebo to inject, and sites will determine if a participant or 
caregiver is willing and able to correctly  perform the SC injection.
On Day  1, the in itial dose of study  intervention administered by  [CONTACT_19972] b y study site personnel to ensure the participant or caregiver is using 
proper technique. 
Vupanorsen or placebo will be administered as a single or double SC in jection at 2 -week or 
4-week intervals depending on the treatment arm. At the study  site or at home, SC injections 
should be administered by  [CONTACT_19973]: upper arm, thigh, o r abdomen quadrant, as preferred b y the 
participant. Participants receiving [ADDRESS_18811] home dosing. 
Study  intervention administration details will be recorded on the CRF.
6.1.2. Medical Devices
1.The sponsor manufactured medical devi ces provided for use in this study  are 
vupanorsen 100 mg/mL  (60 mg/sy ringe), vupanorsen 100 mg/mL (80 mg/syringe), or 
placebo (0 mg/s yringe) for Solution for I njection.
2.Instructions for medical device use are provided in the I P manual.
3.All medical device d eficiencies (including malfunction, use error and inadequate 
labeling) shall be documented and reported b y the investigator throughout the clinical 
investigation (see Section 8.3.8 ) and appropriately  managed by  [CONTACT_456].
6.2.Preparation/Handling/Storage/Accountability
1.The investigator or designee must confirm appropriate temperature conditions have 
been maintained dur ing transit for all study  interventions received and any  
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or admi nister study  intervention. All study  
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and auth orized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18812] participants on the proper storage requirements for take -home 
study  intervention.
7.The investigator, institution, or the head of the medical institution (where ap plicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records), such as the 
IPAL or sponsor -approved equivalent. All study  interventions will be accounted for 
using a stud y intervention accountabilit y form/record. Only  study  intervention 
administered Q2W will be taken home b y the participant; cooler bags will be 
provided for transporting study  intervention from the site to the participant’s home. A 
biohazard sharps container will be provided to the participant for disposal of used 
syringes. When the biohazard sharps container is full or at end of study  or early  
discontinuation visit, the participant will return the biohazard sharps container to the 
study  site for destruction. All study  intervention that is taken home by  [CONTACT_2299], 
both used and unused, must be returned to the investigator b y the participant. 
Returned study  intervention must not be redispensed to the participants.
8.Further guidance and inf ormation for the final disposition of unused study  
interventions are provided in the I P manual. All destruction must be adequately  
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materi als are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y [COMPANY_007].
Upon identification of a product complaint, notify the sponsor within 1 business day  of 
discovery  as described in the I P manual.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 376.2.1. Preparation and Dispensing
Vupanorsen and placebo will be provided as prefilled sy ringes packaged and dispensed in 
cartons with tamper -evident seals. Onl y single -use sy ringes will be used. Study  intervention 
should be dispensed b y an app ropriatel y qualified and experienced member of the study  staff 
(eg, ph ysician, nurse, phy sician’s assistant, nurse practitioner, pharmacy  assistant/technician, 
or pharmacist) as allowed by  [CONTACT_5737], state, and institutional guidance. The qualified staff 
membe r will dispense the study  intervention using an IRT drug management sy stem via 
unique container numbers in the cartons provided and in quantities appropriate to the SoA. A 
second staff member will verify  the dispe nsing. The participant or caregiver should be 
instructed to maintain the product in the cartons provided, and the cartons should not be 
opened until the study  intervention is to be administered. See the IP manual for detailed 
instructions. 
The following p rocedures should be followed to help protect the blind:
Used sy ringes should be placed immediatel y after use, whenever or wherever dosing 
occurs, in a biohazard sharps container, and the container will be returned to the study  
site, as needed, eg, when the biohazard sharps container is full or at end of study /early  
discontinuation visits.
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study Intervention
Allocation of participants to treatment groups will proceed through the use of an IRT s ystem 
(IWR). The site personnel (study  coordinator or specified designee) will be required to enter 
or select information including but not limited to the user’s ID and password, the protocol 
number, and the participant number. The site personnel will then be provided with a 
treatment assignment, randomization number, and DU or container number when stud y 
intervention is being supplied via the I RT s ystem. The I RT sy stem w ill provide a 
confirmation report containing the participant number, randomization number, and DU or 
container number assigned. The confirmation report must be stored in the site’s files. 
Study  intervention will be dispensed at the study  visits listed in the SoA. 
Returned study  intervention must not be redispensed to the participants.
The study -specific I RT reference manual and I P manual will provide the contact [CONTACT_19974] s ystem.
6.3.2. Breaking the Blind
The I RT will be programmed with blind -breaking instructions. I n case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’s 
treatment assignment is warranted. Participan t safety  must alway s be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every  effort to contact [CONTACT_19975] a participant’s t reatment assignment unless this could delay  further management 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 38of the participant. If a participant’s treatment assignment is unblinded, the sponsor must be 
notified within [ADDRESS_18813] information 
and further details on the use of the IRT s ystem.
6.4.Study Intervention Compliance
At site visits, study  interve ntion will be dispensed by  [CONTACT_1719], and 
participants will self -administer (or caregivers will administer) study  intervention under 
medical supervision. The date and time of each dose administered in the clinic will be 
recorded in the s ource documents and recorded in the CRF. The dose of study  intervention 
and study  participant ID will be confirmed at the time of dosing by  a member of the stud y 
site staff other than the person dispensing the study intervention.
Participants receiving stu dy intervention Q2W will receive a diary  to record home dosing. 
When participants self -administer (or caregivers administer) study  intervention at home, 
compliance with study  intervention will be assessed at each on -site visit. Compliance will be 
assessed by [CONTACT_19976]’s diary (Q2W only ), direct questioning, and checking 
empty  cartons during the site visits and documented in the source documents and CRF. 
Deviation(s) from the prescribed dosage regimen should be recorded in the CRF.
A record o f the number of vupanorsen and placebo sy ringes dispensed to and taken by  [CONTACT_19977]. Intervention start and stop dates, including dates for intervention delay s and/or d ose 
reductions, will also be recorded in the CRF.
6.5.Concomitant Therapy
All concomitant medications taken during the study must be recorded with indication, daily 
dose, and start and stop dates of administration. Attempts must be made to not alter the do ses 
and regimens of background lipid lowering therapy (statin and ezetimibe [if applicable]) after 
randomization and for the duration of participation in this study . All participants must be 
questioned about concomitant medication at each visit to the clin ical site.
Hormonal contraceptives that meet the requirements of this study  are allowed to be used in 
participants who are WOCBP (see Appendix 4 ).
6.5.1. Prohibited Therapy During the Study
Use of TG lowering or chole sterol lowering medication (eg, fibric acid derivatives, 
niacin, PCSK9 inhibitors, bile acid sequestrants, bempedoic acid).
Use of TG lowering dietary  supplements (eg, fish oil) and prescription products 
containing omega -3 fatty acids (eg ,Vascepa [icosape nt ethy l]). 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 39Use of warfarin or other coumarins, direct thrombin inhibitors, Factor Xa inhibitors , 
heparins or heparinoids is prohibited during the study .
6.5.2. Prohibited Prior Treatments
Use of an y therap y listed in Section 6.5.1 30 day s prior to Screening.
Prior treatment at an y time with vupanorsen is prohibited.
Prior treatment with an y oligonucleotide (including small interfering ribonucleic acid) 
within 6 months o f Screening or prior treatment with inclisiran within 12 months of 
Screening is prohibited.
Prior administration with an investigational drug within 30 day s (or as determined by  [CONTACT_19978]) or [ADDRESS_18814] dose of study  inter vention used in 
this study  (whichever is longer) is prohibited.
6.5.3. Rescue Medicine
There is no rescue therapy to reverse the AEs observed with vupanorsen ; standard medical 
supportive care must be provided to manage any  AEs. 
6.6.Dose Modification
Dose modific ations will not be performed during this study . 
6.7.Intervention After the End of the Study
No intervention will be provided to study  participants at the end of the study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
Due to unforeseen circumstances, all participants may  not complete the study  as planned. 
Regardless of stud y intervention status, participants should continue in the study  if willing. 
Possible discontinuations may  include:
1.Discontinuation of study  interv ention: Participants will discontinue study  intervention but 
continue in the study .
a.Temporary  discontinuation: I f a participant temporaril y discontinues study 
intervention for an y reason other than safety , they should resume study  intervention at 
the next scheduled dosing, if possible.
b.Definitive discontinuation: I f study  intervention is permanentl ydiscontinued (as 
requested b y the investigator or the participant), the participant will remain in the 
study  to be evaluated during the regular visit schedule ( see Section 7.1.2 and
Section 7.2.1 ).At the time of discontinuing from the study  intervention, if possible, 
an Earl y Termination/Discontinuation visit should be conducted. See the SoA for 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 40assessments to be collected at the time of discontinuation of study  intervention and 
for an y further eva luations that need to be completed.
Whenever possible, restart of study  intervention should be encouraged. Even if an 
Early Termination/Discontinuation visit was completed due to the discontinuation of 
study  intervention, this should not prevent comp lete s tudy follow -up procedures 
including restart of randomized treatment. All efforts must be taken to assure that the 
participant will be seen and assessed b y an investigator. Participants fulfilling a 
study -specific discontinuation criteria should never be re started on study  intervention.
2.Participant discontinuation/withdrawal from the study : Participants will not continue in 
the study  (see Section 7.2).
a.Withdrawal of co nsent (see Section 7.2.1 ).
b.Lost to follow -up (see Section 7.3). 
7.1.Disconti nuation of Study Intervention
7.1.1. Monitoring Criteria
In general, all laboratory  assessments to monitor participant safety  or to determine whether a 
participant may  continue or resume dosing with study  intervention should be done by  [CONTACT_19979] , if possible. L ocal laboratory  testing may  be acceptable in some situations 
and should be discussed by  [CONTACT_19980] a case -by-case basis.
The following laboratory abnormalities require prompt retesting within 7 day s of receipt of 
results:
Any platelet count <100,000 /mm3. The participant should be managed according to 
Appendix 10 flow chart for managing decreased platelet counts.
Any decrease in eGFR of ≥50% from baseline or eGFR <15 mL/min/1.73 m2. The 
participant should be managed according to Appendix 11 flow chart for managing eGFR 
decreases.
Either of the following AST or AL T abnormalities (Note: Participants meeting either of 
the following retesting criteria should be managed according to Appendix [ADDRESS_18815] or ALT. This shoul d also prompt review of Appendix 6
[liver safety ] to determine if additional investigations must be conducted):
Any single AST and/or AL T elevation >3 × ULN for participants with baseline AST 
and ALT within normal limi ts, regardless of accompany ing s ymptoms or total 
bilirubin.
Baseline AST or ALT values above the reference range: AST or ALT values >2 times 
the baseline values AND >3 × ULN, regardless of accompan ying symptoms or total 
bilirubin.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 417.1.2. Discontinuation Criteria
In rare instances, it may  be necessary  for a participant to permanentl y discontinue study  
intervention (definitive discontinuation). Reasons for definitive discontinuation of study  
intervention include the following:
Platelet count is <75,000 /mm3on a re -test (ie, initial platelet count is <100,000 /mm3
and the repeat platelet count is <75,000 /mm3or both the initial and re -test are 
<75,000 /mm3). Refer to Appendix [ADDRESS_18816] be conducted.
The participant’s eGFR falls to <15 mL /min/1.73 m2and confirmed b y a repeat 
laboratory  measurement.
Participant meets criteria for DILI (Hy ’s Law) as defined in Appendix 6 .
AST or ALT elevations are >8 × ULN, confirmed on a repeat laboratory  
measurement, regardless of total bilirubin or accompany ing s ymptoms.
A severe h ypersensitivity  reaction or severe injection site reaction occurs following a 
SC study  intervention dose. Severe h ypersensitivity  reactions are defined as those 
causing anaph ylaxis. Severe injection site reactions are defined as those in which 
ulceration or severe necrosis occurs.
Participant becomes pregnant.
Note that discontinuation of study  intervention does not represent withdrawal from the study .  
If study  intervention is definitively  discontinued, the participant will remain in the study  to 
be evaluated during the regular visit schedule. See the SoA for data to be collected at the time 
of discontinuation of study  intervention and follow -up for any  further evaluations that need 
to be completed.
In the event of discontinuation of study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, posttreatment study  follow -up, 
and/or future collection of additional information.
7.2.Participant Discon tinuation/Withdrawal From the Study
A participant may  withdraw from the study  at an y time at his/her own request. Reasons for
stoppi[INVESTIGATOR_19936]:
Refused further follow -up
Lost to follow -up
Death
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 42Study  terminated by  [CONTACT_19981] r
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow -up and fo r any further evaluations that need to be completed.
Participants should be questioned regarding their reason for withdrawal.  
7.2.1. Withdrawal of Consent
Participants who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified procedures. The only  exception to 
this is when a participant specificall y withdraws consent for an y further assessments or 
contact [CONTACT_19982] y authorized by [CONTACT_19983]. Participants should notify  the investigator of the decision to withdraw consent 
from future follow -up.Participants should be questioned regarding their reason for 
withdrawal. The investigator must inform the TIMI  Hotline of the withdraw al of consent. 
The withdrawal of consent should be explained in detail in the medical records by  [CONTACT_1275], as to whether the participant is onl y stoppi[INVESTIGATOR_19937]/or posttreatmen t study  follow -up, 
and entered on the appropriate CRF page. At the time of withdrawal from the study , if 
possible, an Earl y Termination/Discontinuation visit should be conducted. See the SoA for 
assessments to be collected at the time of study  withdrawal.
If a participant withdraws consent from the stud y, he/she may  request destruction of any  
remaining samples taken and not tested, and the investigator must document any  such 
requests in the site study  records and notify  the sponsor accordingly .
If the participant withdraws consent for disclosure of future information, no further 
evaluations should be performed and no additional data should be collected. The sponsor 
may retain and continue to use any  data collected before such withdrawal of consent.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant’s safet y was preserved.
Publicly  available information should be used to determine vital status (whether the 
participant is alive or dead) only as appropriatel y directed in accordance with local law.
7.3.Lost to Follow -up
To prevent participants being lost to follow -up, their contact [CONTACT_8972], including next of kin 
contacts, should be collected initially  and updated regularl y by [CONTACT_19984]. 
The investigator should educate the participant on the importance of contact [CONTACT_19985] .
Repeated attempts will be made to locate and o btain pertinent medical information for 
participants who are initially  lost to follow -up. A participant will be classified as lost to 
follow -up only  if he/she has failed to return for the required study  visits and his/her vital 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18817] him/her 
via telephone, fax, email, certified letter, or through patient locator agencies (if allowed b y 
national regulation). Where permissible by  [CONTACT_1769], the ICD will include language to grant 
theoption to employ  outside companies to assist in obtaining updated contact [CONTACT_19986] y available source.
8.STUDY ASSESSMENTS AN D PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not a llowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud y design requirements, including those specifie d in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as de scribed. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator must take all steps necessary  to ensure the safe ty and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
The total blood sampling volume for individual participants in this study  is approximately  
250mL. The actual collection times of blood sampling may  change. Additional blood 
samples may  be taken for s afety assessments at times specified b y [COMPANY_007], provided the total 
volume taken during the study  does not exceed [ADDRESS_18818] VLDL -C 
should be collected from participants in a fasted state (see Section 5.3.2 ) as indicated in the 
SoA; non -HDL -C will be calculated as TC –HDL -C.
Lipid results from Day  [ADDRESS_18819] will not be reported to study  sites or other blinded personnel 
until the study  has been unblinded (see Section 8.2.7 for potential exception). 
8.1.2. Lipoproteins and FFA 
Blood samples for measurement of Lp(a), ApoB, ApoB -48, ApoB -100, ApoC -III, ApoA -I, 
and FFA should be collected from participants in a faste d state (see Section 5.3.2 ) as 
indicated in the SoA.
Lipoprotein and FFA results from Day  [ADDRESS_18820] will not be reported to study  sites or other 
blinded personnel until the study  has been unblinded. 
8.1.3. hsCRP
Blood samples for measurement of hsCRP should be collected from participants in a fasted 
state (see Section 5.3.2 ) as indicated in the SoA.
hsCRP results will not be reported to stud y sites or other blinded personnel until the study  
has been unblinded.
8.2.Safety A ssessments
Planned time points for all safety  assessments are provided in the SoA. Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
8.2.1. MRI-PDFF Assessments
At scheduled visits (refer to the SoA), liver fat will be assessed via MRI using the PDFF 
acquisition method. Each assessment will require the participants to be in a supi[INVESTIGATOR_19938]  [ADDRESS_18821] (except water) of ≥4 hours, and as much as 
practicall y possible, at the same time (±2 hours) of the day relative to assessment at 
Screening.
Across the stud y sites selected for this study , the sponsor -identified central imaging vendor 
will train the imaging facility  staff on the MRI -PDFF acquisition protocol, on just -in-time 
review of the acquired images for assessment of images being deemed ev aluable, and on 
transfer (preferabl y electronically) of the images to the sponsor -identified central imaging 
vendor for anal ysis and quantification of liver fat. Only the staff members at the imaging 
facility who are trained by [CONTACT_456] -identified centr al imaging vendor are permitted 
to acquire images ; however in rare/limited situations, exceptions may  be granted with 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 45written approval of the sponsor. Complete details on the MRI -PDFF acquisition protocol, 
determination of quality  of images, and transmissi on of data to sponsor -identified central 
imaging vendor will be provided in an Imaging Manual provided to the sites prior to the start 
of the study .
As much as practicall y possible, analysis of the MRI -PDFF images acquired at baseline and 
Week 24 will be u ndertaken by  a single reviewer at the sponsor -identified central imaging 
vendor who will be blinded to individual participant’s clinical data, as well as randomization 
assignment. MRI -PDFF images will be blinded to study  sites, blinded personnel, participa nts, 
and sponsor until the study  has been unblinded.  
[IP_ADDRESS]. Management of Incidental Findings
An incidental finding is one unknown to the participant that has potential health or 
reproductive importance, which is discovered unexpectedly  in the course of a resea rch study  
but is unrelated to the purpose and bey ond the aims of the study . The images will be 
reviewed b y a sponsor -identified central review facility . The purpose of this review is to 
evaluate images for the amount of fat in the liver. Central image revi ew is not a complete 
medical review of the participant. If, during the central review process, an unexpected 
observation is identified and this finding could, in the opi[INVESTIGATOR_19939], have a 
significant health or reproductive consequence, th is finding may  be shared with the study  
sponsor for disclosure to the PI . All follow -up testing and final diagnosis will be left to the 
discretion of the medical professionals at the site or those with an existing phy sician -
participant relationship. The PI [INVESTIGATOR_19940] y AEs identified from 
incidental findings as described in the AE reporting section. Identification of such incidental 
findings during the central review process should not be expected, and the site maintains 
responsibil ity for performing a general safet y review of all images as per site protocols.
8.2.2. Physical Examinations
Physical examination will be performed at Screening.
A complete ph ysical examination will include, at a minimum, assessments of the 
cardiovascular, respir atory , gastrointestinal, and neurological s ystems.
Height will be measured and recorded at Screening, and weight will be measured and 
recorded at Screening, Day  1, Day  169, and Earl y Termination/Discontinuation, if applicable 
(see SoA).
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses. 
8.2.3. Vital Signs
Single seated blood pressure and pulse rate will be assessed at times specified in the SoA
with a completel y automated device. Manual techniques will be used only if an automated 
device is not available.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18822] 
for th e participant in a quiet setting without distractions (eg, television, cell phones).
8.2.4. Electrocardiograms
Standard 12 -lead ECG utilizing limb leads (with 10 second rh ythm strip) should be collected 
at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals, and QRS 
complex. Alternative lead placement methodology  using torso leads (eg, Mason -Likar) 
should not be done given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. 
All scheduled 12-lead ECGs should be performed with the participant in a supi[INVESTIGATOR_12251];
ECG values of potential clinical concern are listed in Appendix 7 . 
If a machine -read QTc value is prolonged, as defined in Appendix 7 , repeat 
measurements may  not be necessary  if a qualified phy sician’s interpretation 
determines that the QTc values are in the acceptable range;
Assessment of whether prolonged QTc interval meets criteria as defined in 
Appendix [ADDRESS_18823] assess QTc interval using only the Fridericia’s correction (ie, 
QTcF) either as reported by  [CONTACT_941] 12 -lead ECG machine or QTcF derived using 
sponsor -provided tool and reported QT and RR intervals. 
In some cases, it may  be appropriate to repeat abnormal 12 -lead ECG to rule out 
improper lead placement as contributing to the ECG abnormality ; as much as practical ly 
possible, it is important that leads be placed in the same positions each time in order to 
achieve precise ECG recordings.
8.2.5. Clinical Safety Laboratory Assessments
See Appendix [ADDRESS_18824] be conducted in accordance with the 
laboratory  manual and the SoA. Note: safety laboratory results from W eek1 visit should be 
reviewed by [CONTACT_19965] [ADDRESS_18825] any  
clinically  relevant changes occurring during the study  in the AE section of the CRF.  
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease under study , unless judged by  [CONTACT_19988]'s condition.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18826] dose of study  intervention should 
be repeated until the values return to normal or baseline or are no longer considered clinicall y 
significant b y the investigator or TIMI Hotline.
If such va lues do not return to normal/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified as much as possible and the sponsor 
notified.
See Appendix [ADDRESS_18827] 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA. 
Following a negative pregnancy  test result at Screening, appropriate contraception must be 
commenced and a second negative pregnancy  test result will be required at the baseline visit 
prior the partic ipant’s receiving the study  intervention. Pregnancy  tests will also be done 
whenever 1 menstrual cycle is missed during the active treatment period (or when potential 
pregnancy  is otherwise suspected) and at the end of the study .  Pregnancy  tests may  also be 
repeated if requested b y IRBs/ ECs or if required by [CONTACT_427]. If a urine test cannot 
be confirmed as negative (eg, an ambiguous result), a serum pregnancy  test is required. In 
such cases, the participant must be excluded and discontinued from study  intervention if the 
serum pregnancy  result is positive.
8.2.7. Potential Severe Cases of Hypertriglyceridemia
In certain circumstances, unblinding of TG results may  occur during the study . In the event a 
participant’s fasting (see Section 5.3.2 ) TG is >1000 mg/dL, as reported b y the sponsor -
identified central laboratory , the investigator and sponsor will receive an alert from the 
laboratory  along with the unblinded TG l evel. The investigator is to repeat the TG test via the 
central laboratory , ideally  within 7 day s of receipt. The investigator should counsel the 
participant on diet and lifesty le factors to improve the TG level prior to the repeat 
measurement. For partici pants with a confirmed TG value of >1000 mg/dL, the investigator 
will again counsel the participant on diet and lifesty le, and the investigator can titrate the 
statin dose (if applicable) or can add a medication to lower TG at the investigator’s 
discretion . In only  these circumstances (confirmed TG value of >1000 mg/dL ), the prohibited 
TG lowering medications in Section 6.5.1 are not applicable. 
8.3.Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
The definitions of device -related safet y events (ADEs and SADEs) can be found in 
Appendix 8. Device deficiencies are covered in Section 8.3.8 .
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 48AEs will be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the partic ipant's legall y authorized representative). 
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate informa tion both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE (see Appendix 3 ) or caused the 
participant to discontinue the study  intervention (see Section 7.1).
Each participant will be questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain spe cific follow -up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention), through and including a 
minimum of [ADDRESS_18828] SAE Report Form.
Investigators are not obligated to activel y seek AEs or SAEs after the participant has 
concluded stud y participation . However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has completed the study, and he/she considers the event 
to be reasonably  related to the study  intervention, the investigator must promptly  report the 
SAE t o [COMPANY_007] using the CT SAE Report Form.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in
Section 8.3.[ADDRESS_18829] SAE Rep ort Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 49Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24hours of it being avai lable.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period , 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_18830] on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, a nd assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visit s/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow -up (as defined in Section 7.3 ).
In general, follow -up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as co ncomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix 3.
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_19990] y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigatio n. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]Rs according to local regulatory  
requiremen ts and sponsor policy  and forwarded to investigators as necessary .
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 50An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study  and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the study  intervention under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention.
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception.
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below areexample sof 
environmental exposure during pregnancy :  
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_19991].
A male famil y member of healthcare provider who has been exposed to the study  
intervention by  [CONTACT_19992].
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until [ADDRESS_18831] dose. 
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 51Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP repo rts with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP Supplemental Form. In the case of a live birth, the structur al 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_19993] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs.  If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Addition al information about pregnancy outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion including miscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_18832] 
to causality ,as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested b y the sponsor. Further 
follow -up of birth outcomes will be handled on a case -by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnan t Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if:
A female participant is found to be breastfeeding while receiving stud y intervention 
or for a minimum of 21 weeks after discontinuing study  intervention.
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the st udy intervention 
by [CONTACT_19991].  
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18833] SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when a person receives unplanned direct contact [CONTACT_19994], which may  or may  not lead to the occurrence of an AE. Such persons may  
include healthcare providers, famil y members, and other roles that are involved in the trial 
participant’s care.
The investigator must report occupational e xposure to [COMPANY_007] Safet y within 24 hours of the 
investigator’s awareness, regardless of whether there is an associated SAE. The information 
must be reported using the CT SAE Report Form. Since the information does not pertain to a 
participant enrolled in t he study , the information is not recorded on a CRF; however, a copy  
of the completed CT SAE Report Form is maintained in the investigator site file.
8.3.6. Cardiovascular and Death Events
Cardiovascular and death events will be reported according to Adverse Event reporting 
procedures.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs 
Disease -related events are not applicable to this study .
8.3.8. Adverse Events of Special Interest 
Injection site reactions are AESI. In case of acute injection site reactions, the Investigator 
should institute treatment measures deemed medically  appropriate such as topi[INVESTIGATOR_19941]. Such events and treatments are to be captured and reported on the 
appropriate CRF. If an injection site reaction occurs at more than 1 injection site location, 
each location should be captured as a separate injection site AE. For each injection site AE, 
an injection site assessment should be conducted an d captured on the CRF. A separate 
injection site assessment should be conducted for each injection location where an injection 
site reaction occurs. The site should also complete the injection site reaction assessment and 
all concomitant treatments should be recorded and captured in the CRF, together with the 
Adverse Event of injection site reactions. AEs should be reported as serious per the criteria in 
Section 10.3.2 .
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 53Additional AESI  include i ncreases in ALT/AST, decreases in platelet count, or decreases in 
eGFR (as described in Section 7.1.1 )that result in a missed dose due to temporary  dose 
interruption or permanent discontinuation .
All AESI s must be reported as an AE or SAE following the procedures described in 
Sections 8.3.[ADDRESS_18834] SAE Report Form.
[IP_ADDRESS]. Lack of Efficacy
Lack of efficacy  is reportable to [COMPANY_007] only  if associ ated with an SAE (see Section 10.3.1 ).
8.3.9. Medical Device Deficiencies
Medical devices are being provided for use in this study  as the stud y intervention is supplied 
in prefilled sy ringes. In order to fulfill regulatory  reporting obligations worldwide, the 
investigator is responsible for the detection and documentation of events meeting the 
definitions of device deficiency  that occur during the study  with such devices.
The definition of a medical device deficiency  can be found in Appendix 8 .
NOTE: Deficiencies fulfilling the definition of an AE/SAE will also follow the processes 
outlined in Sections 8.3.1 through 8.3.4 and Appendix 3 of the protocol.
[IP_ADDRESS]. Time Period for Detecting Medical Device Deficiencies
Medical device deficiencies or malfunctions of the device will be detected, documented, and 
reported during all periods of the study  in which the medical device is used.
If the investigator learns of an y device deficiency at an y time after a participant has been 
discharg ed from the study , and such incident is considered reasonabl y related to a medical 
device provided for the study , the investigator will promptly  notify  the sponsor.
The method of documenting medical device deficiencies is provided in Appendix 8 .
[IP_ADDRESS]. Follow -up of Medical Device Deficiencies
Follow -up applies to all participants, including those who discontinue study  intervention.
The investigator is responsible for ensuring that follow -up includes an y supplemental 
investig ations as indicated to elucidate the nature and/or causality  of the deficiency .
New or updated information will be recorded on a follow -up form with all changes signed 
and dated b y the investigator.
[IP_ADDRESS]. Prompt Reporting of Device Deficiencies to Sponsor
Device deficiencies will be reported to the sponsor within [ADDRESS_18835] be reported to [COMPANY_007] Safet y 
within 24 hours upon the investigator’s awareness as outlined in Sections [IP_ADDRESS] and8.3.1.[ADDRESS_18836] for the receipt of device deficiency  information.
[IP_ADDRESS]. Regulatory Reporting Requirements for Device Deficiencies
The investigator will promptly  report all device deficiencie s occurring with any  medical 
device provided for use in the study  in order for the sponsor to fulfill the legal responsibility  
to notify  appropriate regulatory  authorities and other entities about certain safet y information 
relating to medical devices bein g used in clinical studies.
The investigator, or responsible person according to local requirements (eg, the head of the 
medical institution), will comply  with the applicable local regulatory  requirements relating to 
the reporting of device deficiencies to the IRB/EC.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by  [CONTACT_19995], or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under study  may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to [COMPANY_007] Safety Within 24 
Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  ifassociated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study  participant .
Injection administered via an y route (ie, intramuscular, intravenous) other than SC.
Injection administered in a location other than upper arm, thigh, or abdomen 
quadrant.
For dose regimens requiring 2 injections, both injections administered at the same
injection site.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 55Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified withi n 24 hours.
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recor ded on the AE page of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_18837] SAE Report 
Form only when associated with an SAE.
8.4.Treatment of Overdose
For this study , any  dose of vupanorsen greater than 320 mg (more than four 80 mg/placebo 
syringes or more than five 60 mg/placebo s yringes) given within a 21 -day period will be 
considered an overdose.
Sponsor does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator/treating physician should:
1.Contact [CONTACT_19996] 24 hours .
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities until 
vupanorsen can no longer be detected s ystemically  (at least 5 half -lives [ie, 
150days]).  
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to Safety  only when associated with an SAE.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_19997].   
8.5.Pharmacokinetics
For all participants, trough and post -treatment concentrations of vupanorsen in plasma (as 
total full -length oligonucleotides, including full y conjugated, partiall y conj ugated, and 
unconjugated vupanorsen ) will be determined as specified in the SoA. A listing of individual 
vupanorsen concentration sorted by  [CONTACT_1570], participant ID, planned visit, visit date 
and time, and time post the most recent dose will be reported and summarized by  [CONTACT_19998]. Population PK and PK/PD analy ses may be explored using the combined data from 
thisstudy  and other clinical studies of vupanorsen and reported in a separate population 
analysis report.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 56Blood samples of approximately  4mL will be collected in K2 EDTA tubes, to provide a 
minimum of 2 mL  plasma for measurement of plasma concentrations of vupanorsen from 
participants in a fasted state (see Section 5.3.2 ). Instructions for the collection and handling 
of biological samples will be provided in the laborat ory manual or by  [CONTACT_456]. The actual 
date and time (24 -hour clock time) of each sample will be recorded.
Samples will be used to evaluate the PK of vupanorsen . Each plasma sample will be divided 
into 2 aliquots. Samples collected for anal yses of vupano rsen plasma concentration may  also 
be used to evaluate safety or efficacy  aspects related to concerns arising during or after the 
study , for metabolite identification and/or evaluation of the bioanal ytical method, or for other 
internal exploratory  purposes.
Samples collected for measurement of plasma PK concentrations of vupanorsen will be 
analyzed using a validated anal ytical method in compliance with applicable SOPs. Potential 
metabolites may  be anal yzed with either validated or exploratory method s.
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity .Any deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim stora ge or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor.  
On a case -by-case basis, the sponsor may  make a determination as to whether sample 
integrit y has been compromised.
Drug concentration information that may unblind the study  will not be reported to 
investigator sites or blinded personnel until the study  has been unblinded.
Any changes in the timing or addition of time points for any  planned PK study  assessments 
must be documented and then archived in the sponsor and site study  files, but will not 
constitute a protocol deviation . 
8.6.Pharmacodynamics
Serum ANGPTL3 will be measured as the target PD endpoint in this study .
Blood sa mples of approximately  4mL, to provide a minimum of 2 mL  serum, will be 
collected for measurement of ANGPTL3 from participants in a fasted state (see 
Section 5.3.2 ) as specified in the SoA.
As part of understanding the PD of the study  intervention, samples may  be used for 
evaluation of the bioanalytical method, as well as for other internal exploratory  purposes.  
Samples will be analy zed using a validated anal ytical method in compliance with applic able 
SOPs.
The PD samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity . Any  deviations from the PD sample 
handling procedure (eg, sample collection and processing steps, interim storage, or shippi[INVESTIGATOR_19942] C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 57conditions), including any actions taken, must be documented and reported to the sponsor. 
On a case -by-case basis, the sponsor may  make a determination as to whether sample 
integrit y has been compromised.
ANGPTL 3 results will not be reported t o investigator sites during the study .
8.7.Genetics
8.7.1. Specified Genetics
Genetics (specified anal yses) are not evaluated in this study .
8.7.2. Banked Biospecimens for Genetics
A 4-mL blood sample optimized for DNA isolation (Prep D1) will be collected as local 
regulations and IRBs/ECs allow. 
Banked Biospecimens may  be used for research related to the study  intervention(s) and 
dyslipi[INVESTIGATOR_19943]. Genes and other analy tes(eg, proteins, RNA, nondrug 
metabolites) may  be studied using the banked samples. 
See Appendix 5 for information regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in the Central Laboratory  Manual.
8.8.Biomarkers
Biomarkers are not evaluated in this study . 
8.8.1. Banked Biospecimens for Biomarkers
Additional Banked Biospecimens in this study  are:
6-mL whole blood (Prep B1 .5) will be collected and isolate plasma reta ined.
6-mL whole blood (Prep B2 .5) will be collected and isolate serum retained.
5-mL urine (Prep M4) will be collected and retained.
Banked Biospecimens will be collected as local regulations and IRB/ECs allow.  
Banked Biospecimens may  be used for resear ch related to the study  intervention(s) and 
dyslipi[INVESTIGATOR_035]. Genes and other anal ytes (eg, proteins, RNA, nondrug metabolites) may  be 
studied using the banked samples. 
See Appendix 5 for information regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in central laboratory  manual. 
8.9.Immunogenicity Assessments
Immunogenicit y of vupanorsen will be assessed before, during, and after treatment. A listing 
of individual plasma ADA results (including ADA positive, negative, and unknown status 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 58samples and titers) sorted by  [CONTACT_1570], participant ID, planned visit, and the visit 
date/time will be reported. The incidence (number) and incidence rate (percent) of ADA 
positive, negative and unknown participants will be summarized by  [CONTACT_19999] . The ADA positive participants will be further 
subcategorized into TEADA if the baseline ADA is ne gative. The incidence and incidence 
rate of TEADA will be summarized by  [CONTACT_20000] .  
Potential relationships of immunogenicit y with selected efficacy, safet y, and PK 
concentrations may  be evaluated.
Blood samples of approximately  6mLwill be collected in K2 EDTA tubes , to provide a 
minimum of 3 mLplasma for determination of ADA as specified in the SoA.Instructions for 
the collection and handling of biological sam ples will be provided in the laboratory  manual 
or by  [CONTACT_456]. The actual date and time (24 -hour clock time) of each sample will be 
recorded.
Samples collected for determination of ADA may  also be used for additional characterization 
of the immune respo nse or for other internal exploratory  purposes. These data will be used 
for internal exploratory  purposes.
Samples will be analy zed using a validated anal ytical method in compliance with applicable 
SOPs. Samples determined to be positive for ADA may  be fur ther characterized.
The immunogenicit y samples must be processed and shipped as indicated in the instructions 
provided to the investigator site to maintain sample integrity .Any deviations from the 
immunogenicit y sample handling procedure (eg, sample colle ction and processing steps, 
interim storage, or shippi[INVESTIGATOR_19944]), including any  actions taken, must be documented 
and reported to the sponsor. On a case -by-case basis, the sponsor may  make a determination 
as to whether sample integrit y has been comprom ised.
No immunogenicit y data will be provided to study sites, blinded personnel, or the study  team
until the study  has been unblinded.
8.10. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDER ATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in the SAP, which will be maintained by [CONTACT_456].  
The SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be reflected in a 
protocol amendment.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18838] of the drug when taken as directed. It includes the following 
4attributes: 
Population: Participants with dy slipi[INVESTIGATOR_19923] a statin who meet the 
inclusion/exclusion criteria .
Variable: The percent change from baseline in non -HDL -C at Week 24.
Intercurrent event: All off -treatment data (ie, occurring at least 1 dosing interval after 
discontinuation of treatment), or data collected post treatment of severe 
hypertrigly ceridemia (ie, change in statin dose or addition of TG lowering therapy ; 
Section 8.2.7 ), if collected, will be excluded from anal ysis.  
Population -level summary: Difference of variable means between vupanorsen and 
placebo.
9.2.Sample Size Determina tion
Assuming a common standard deviation of 17.5% (observed in the Month 6 data of the 
Phase 2a proof -of-concept and dose -ranging study ) for the percent change from baseline in 
non-HDL -C at Week 24 and a treatment discontinuation rate of 15%, 20 partici pants per arm 
will correspond to a 95% CI  of point estimate ±11.76% for the difference of treatment effect 
(versus placeb o). These parameters correspond to a power of 91.5% using a 2-sided alpha of
0.05,to detect a difference of -20%, without adjustment f or multiple comparison to placebo.
A permutation block schedule will be used in enrollment within each arm, including 
vupanorsen and matching placebo. If enrollment is stopped for the 160 mg Q2W arm (see 
Section 4.1), the corresponding matching placebo enrollment will also be stopped.
9.3.Analysis Set
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis Set Description
Enrolled/Randomly  
assigned to stud y 
intervention"Enrolled" means a participant's, or their legall y authorized 
representative’s, agreement to participate in a clinical study  
following completion of the informed consent process. 
Potential participants who are screened for the purpose of 
determining eligibility  for the study , but do not participate in 
the study , are not considered enrolled.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18839] -discontinuation will be 
included in the anal ysis set.
9.4.Statistical Analyses
The SAP will be developed and finalized before any  anal yses are performed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.  
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.4.1. General Considerations
The primary  statistical metho d of MMRM will apply  to continuous endpoints.
Statistical efficacy  comparison will be made between each dose of vupanorsen and placebo 
for primary  and secondary  endpoints, respectivel y. Placebo -adjusted LS mean difference, 
95% CI , and p -value will be prese nted. Since this study  is exploratory  in nature, no 
multiplicity  adjustment of endpoints nor adjustment of multiple comparison to placebo will 
be made. Sensitivity  analy ses/supplementary  analy ses are defined in the SAP. Since the visit 
after Week 24 is con sidered safet y follow -up, the statistical analy ses at those visits will be 
presented but the p -value will be treated onl y as nominal.
In addition, a Bay esian E max dose-response model will be estimated to illustrate the expected 
relationship between doses a nd their corresponding (percent) change from baseline at 
Week 24 for primary  and key  secondary  endpoints, respectivel y. For each endpoint, 95% CI  
at each studied dose level will also be constructed.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18840] measurem ent prior to the randomization visit 
will be used. However, f or non -HDL -C and other lipid parameters, the baseline value will be 
calculated using the average of all values obtained at Screening and on Day 1 prior to dosing, 
except that for TG, when the ini tial value is exclusionary, the repeat value after the initial 
value and Day  1 value will be used to derive the baseline value. 
In addition to analy ses, summary  statistics, listings, and figures will be provided.
9.4.2. Primary Endpoint(s)
The treatment effect of vupanorsen relative to placebo on the mean percent change/reduction 
from baseline in non -HDL -C at Week 24 will be estimated from the MMRM using the 
FAS_Primary  anal ysis set, ie, assuming all participants in the anal ysis maintain the ir 
randomized treatments. The L S-mean percent change from baseline at Week 24 along with 
95% CI  for each treatment group and placebo -adjusted L S-mean at Week 24 along with 95% 
CI and p -value for each vupanorsen treatment group will be presented. 
A Bay esian Emax dose-response model will be also be estimated using the FAS_Primary  
analysis set, incorporating with the prior distribution of the E max model parameters estimated 
from the Phase 2a stud y. Sensitivity  analy ses will also be performed to evaluate the 
robustness of the primary anal ysis results (details are covered in the SAP).
9.4.3. Secondary Endpoint(s)
No multiplicity  adjustments will be applied to secondary  endpoints. All secondary  endpoints 
will be primarily  anal yzed using the FAS_Primary anal ysis set.
For continuous secondary endpoints, MMRM analy ses will be implemented, with both 
LS-mean and placebo -adjusted L S-mean along with 95% CI , p-value at Weeks 4, 8, 12, 16, 
20, and 24 estimated. The same t ype of Bayesian E max dose-response model will be estimat ed 
using the FAS_Primary  analy sis set for each of the key  secondary  endpoints respectivel y. 
Sensitivity  analy ses will also only  be performed on key  secondary  endpoints (details are 
covered in the SAP).
9.4.4. Tertiary/Exploratory Endpoint(s)
No multiplicity  adjustments will be applied. All tertiary /exploratory  endpoints will be 
analyzed using the FAS_Primary  anal ysis set. 
For continuous tertiary /exploratory  endpoints except for PK, MMRM analy ses will be 
implemented, with both LS -mean and placebo -adjusted L S-mean along with 95% CI , p-value 
at Weeks 4, 8, 12, 16, and 24 estimated.
Listings of individual vupanorsen PK concentration values will be provided.
9.4.5. Other Safety Analyse(s)
All safet y anal yses will be performed on the safet y population.
From the safet y pers pective, the following key  laboratory  endpoints will be explored:
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 62Change and percent change from baseline in HFF at Week 24 
Change from baseline in eGFR 
Change from baseline in AL T/AST 
Percent change from baseline in UACR
Percent change from baseline in platelet counts
Summary  of ALT/AST abnormalities
Summary  of confirmed thrombocy topenia
TEAEs, SAEs, death, injection site reactions, ADA, ECGs, vital signs, immunogenicit y, and 
other safet y laboratory  data, including categorical abnormalities in laborator y data, will be 
summarized/analy zed, listed, or presented in figures by  [CONTACT_20001] b y visit where appropriate. All safet y data, including data collected post the 
occurrence of intercurrent events, will be reported.
[IP_ADDRESS]. Electrocar diogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR 
interval, and QRS complex will be summarized by [CONTACT_10659].
The number (%) of participants with maximum post -dose QTc values and maximum 
increa ses from baseline in the following categories will be tabulated by  [CONTACT_3148]: 
Safety QTc Assessment
Degree of 
ProlongationMild (msec) Moderate (msec) Severe (msec)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >60
In addition, the number of participants with uncorrected QT values >500 msec will be 
summarized.
9.4.6. Other Analyses 
Pharmacogenomic or biomarker data from Banked Biospecimens may  be collected during 
the trial and retained for future analy ses; the results of such anal yses are not planned to be 
included in the CSR. 
The population PK anal ysis will be performed using vupanorsen concentration data pooled 
from this study  and previous studies and may  be reported separatel y from the main CSR. 
Exploratory  PK/PD analy ses may  also be performed for further characterization of biomarker 
and efficacy  effects, eg, ANGPTL 3, non -HDL -C, and TG levels.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18841] approximate ly 16 weeks after 50% of the planned participants (ie, approximately  
110participants), with the exception of the 160 mg Q2W group, are randomized. I nterim 
analysis results, which will include all available data from enrolled participants at the time of 
data cutoff, may  be used for internal business decisions regarding future study  planning or 
adapting the study  after the interim anal ysis. Before an y interim anal ysis is instigated, the 
details of the objectives, decision criteria, dissemination plan, and me thod of maintaining the 
study  blind as per [COMPANY_007]’s SOPs will be documented and approved in a DMC charter. In 
addition, the anal ysis details must be documented and approved in an interim analy sis SAP 
or the finalized SAP.
9.6.Data Monitoring Committee or Other Independent Oversight Committee 
This study  will use an E -DMC. The E -DMC is independent of the stud y team and includes 
only external members. The E -DMC charter describes the role of the E -DMC in more detail.
The E -DMC w ill be responsible for ongoing, unblinded monitoring of the efficacy  and safet y 
of participants in the study  according to the charter. The recommendations made by  [CONTACT_941] 
E-DMC to alter the conduct of the study  will be forwarded to the appropriate [COMPANY_007] 
perso nnel for final decision. [COMPANY_007] will forward such decisions, which may  include 
summaries of aggregate anal yses of safet y data, to regulatory authorities, as appropriate. 
10.SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, E thical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declar ation of Helsinki and CI OMS International Ethical Guidelines;
Applicable ICH GCP guidelines;
Applicable laws and regulations, including applicable privacy  laws.
The protocol, protocol amendments, I CD, SRSD(s), and other relevant documents (eg, 
advertisemen ts) must be reviewed and approved by  [CONTACT_20002] I RB/EC 
by [CONTACT_20003] b y the IRB/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
chan ges made to the study design, except for changes necessary to eliminate an immediate 
hazard to study  participants.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 64The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable local regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and ri sks of the study  
intervention, [COMPANY_007] should be informed immediately .
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of any serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of.
10.1.2. Financial Disclosure
Investigators and sub -investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponso r to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and for 1 y ear after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant and answer all questions regarding the study . The participant should be given 
sufficient time and opportun ity to ask questions and to decide whether or not to participate in 
the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, HI PAA requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of data relate d to the study , and possible risks 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 65associated with participation, including the risks associated with the processing of the 
participant’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_20005], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was obtain ed.  
The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study .
A cop y of the ICD(s) must be provided to the participant.
Participants who are rescreened are required to sign a new ICD.
Unless prohibited by  [CONTACT_20006]/EC decision, the I CD will contain a separate 
section that addresses the use of samples for optional additional research. The optional 
additional research does not require the collection of an y further samples. The investigator or 
authorized designee will explain to each participant the objectives of the additional research.  
Participants will be told that they  are free to refuse to participate and may withdraw their 
consent at an y time and for an y reason during the storage period. A separate signature [CONTACT_20030] a participant's agreement to allow specimens to be used for additional 
research. Participants who decline to participate in this optional additional research will not 
provide this separate signature.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of pa rticipant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access. The study  site will im plement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18842] to the processing of personal 
data, participants will be assigned a single, participant -specific nu merical code. Any  
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], par ticipant -specific code. The study  site will 
maintain a confidential list of participants who participated in the study , linking each 
participant’s numerical code to his or her actual identity  and medical record ID. In case of 
data transfer, the sponsor wil l protect the confidentiality  of participants’ personal data 
consistent with the clinical study  agreement and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through p osting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the req uirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007] -sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical lo cation in which the study  is conducted. These results are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].
EudraCT
[COMPANY_007] posts clinical trial results on EudraCT for [COMPANY_007] -sponsored interventional studies in 
accordanc e with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -spon sored interventional studies at the same time the corresponding study  results are 
posted to www.clinicaltrials.gov.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 67Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy , includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods. Clinical data, u nder Phase 2 of this 
policy , includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centralized procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient -level data or full CSRs for the purposes 
of “bona -fide scientific research” that contributes to the scientific und erstanding of the 
disease, target, or compound class. [COMPANY_007] will make available data from these trials 
24months after study  completion. Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have perso nally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
The investigator must maintain accurate documentation (s ource data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent acces s by [CONTACT_20011].
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. I tis important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk -based ini tiatives in operations and quality  
such as risk management and mitigation strategies and anal ytical risk -based monitoring), 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 68methods, responsibilities, and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring), are provided in the 
monitoring plan.
The sponsor or designee is responsible for the data management of this study , including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  appr oved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for [ADDRESS_18843] ensure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_19945] y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the sponsor or its a gents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Before response 
submission to the regulatory  authorities, the investigator will provide the sp onsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical re cords or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what constitutes source data can be found in the Study  Monitoring Plan.
Description of the use of computerized sy stem is documented in the Dat a Management Plan.  
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18844] participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/CRO if requested to do so by  [CONTACT_20012] I RB/EC or if such termination is 
required to protect the health of study  participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, th e requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development.
If the stud y is prematurely termin ated or suspended, the sponsor shall promptly  inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO(s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The inve stigator shall promptly  inform the participant and should assure 
appropriate participant therap y and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1 y ear after the end of the study  
(or study  termination), whichever comes first. 
The investigator agrees t o refer to the primary  publication in any  subsequent publications 
such as secondary  manuscripts, and submits all manuscripts or abstracts to the sponsor and 
academic leadership [ADDRESS_18845] editorial and ethical practice, the 
sponsor will support publication of mult icenter studies only  in their entirety and not as 
individual site data.  I n this case, the coordinating investigator [INVESTIGATOR_19947].
Authorship of publications for the overall study  results will be determined by  [CONTACT_20014]. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_8860]'s appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_20015]/study  portal. 
To facilitate access to appropriatel y qualified medical personnel on study -related medical 
questions or problems, participants are provided with a contact [CONTACT_20016]. The contact [CONTACT_4662], at a minimum, protocol and study  intervention identifiers, 
participant numbers, contact [CONTACT_19297] t he investigator site, and contact [CONTACT_4664] a 
contact [CONTACT_20017] a medical question or problem originating from another healthcare professional not 
involved in the participa nt’s participation in the study . The contact [CONTACT_20018]; however, it 
should be used only  in the event that the established communication pathway s between the 
investigator site and the study  team are not available. I t is therefore intended to augment, but 
not replace, the established communication pathway s between the investigator site and the 
study  team for advice on medical questions or problems that may  arise du ring the study . The 
contact [CONTACT_8865] b y the participant directl y, and if a participant calls 
that number, he or she will be directed back to the investigator site.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 7110.2. Appendix 2: Clinical Laboratory Tests
The following clinical lab oratory  tests will be performed at times defined in the SoA section 
of this protocol. Additional laboratory  results may  be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer us ed by  [CONTACT_20019] , or as derived 
from calculated values. These additional tests would not require additional collection of 
blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during the 
study  to assess an y perceived safet y issues.
Clinical Che mistry Panel Hem atology Panel Urinalysis Lipid Panel
Sodium
Potassium
Chloride
Bicarbonate
Total protein
Albumin
Calcium
Magnesium
Glucose
BUN
Creatinine
eGFR based on CKD -
Epi
Uric acid
Total bilirubin
Direct (conjugated) 
bilirubin
Indirect 
(unconjugated) 
bilirubin
AST
ALT
Alkaline phosphataseRed blood cells
Hem oglobin
Hem atocrit
MCV, MCH, MCHC
Platelets
WBC differential
     (% and absolute)
Neutrophils
Eosinophils
Basophils
Lymphocytes
MonocytesRoutine urinalysis
  -Color
  -Appearance
  -Specific gravity
  -pH
  -Protein
  -RBC
  -Glucose
  -Ketones
  -Bilirubin
  -Urobilinogen
  -Leukocyte   
     esterase
  -Nitrate
Microscopic 
examination 
(reflex testing 
based on 
urinalysis results)
A/C ratio (UACR)Total cholesterol
LDL cholesterol –
direct measurement
HDL cholesterol
Non-HDL 
cholesterol
Triglycerides
VLDL cholesterol 
–direct 
measurement
Extended Lipoprotein 
Panel, FFACoagulation Pharm acokinetics Immunogenicity
Lp(a)
ApoB
ApoB -48
ApoB -100
ApoC -III
ApoA -I
FFAaPTT (sec)
PT (sec)
INRVupanorsen
concentration in 
plasmaAnti-vupanorsen
antibodies in 
plasma
PD Inflammatory Other
ANGPTL3 hsCRP FSHa
Pregnancy test 
(-hCG), urine 
and serumb
HbA1c
a.For confirmation of postmenopausal status only.
b.For female participants of childbearing potential.
Investigators must document their review of each laboratory  safet y report.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 72Lipid panel results, extended lipoprotein panel results, and inflammatory  results that could 
unblind the study  will not be reported to study  sites or other blinded personnel until the study  
has been unblinded. 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 7310.3. Appendix 3: Adverse Events: Definitions a nd Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally  associated with the use of study  intervention .
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, consid ered clinicall y significant in the 
medical and scientific judgment of the investigator. An y abnormal laboratory test 
results that meet an y of the conditions below must be recorded as an AE:
Is associated with accompany ing s ymptoms.
Requires additional diagnostic testing or medical/surgical intervention.
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the st art of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be report ed as 
an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self -harming intent. Such overdoses should be reported regardless of 
sequelae.
The signs, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  will 
be reported as an AE or SAE if they  fulfill the definition of an AE or SAE and meet 
the requirements as per Section [IP_ADDRESS] . Also, “lack of efficacy ” or “failure of 
expected pha rmacological action” does not constitute an AE or SAE.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 74Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s c ondition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated da y-to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_19948], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hosp italization” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 75This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should b e exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospi[INVESTIGATOR_19951] o r surgical intervention to 
prevent one of the other outcomes listed in the above definition. These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at ho me for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.
Suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic or 
non-pathogenic, is consi dered serious.  The event may  be suspected from clinical 
symptoms or laboratory  findings indicating an infection in a patient exposed to a 
[COMPANY_007] product.  The terms “suspected transmission” and “transmission” are 
considered s ynon ymous.  These cases are co nsidered unexpected and handled as 
serious expedited cases by [CONTACT_20020].  Such cases are also 
considered for reporting as product defects, if appropriate.
10.3.3. Recording/Reporting and Follow up of AEs and/or SAEs
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording adverse events on the CRF 
and for reporting serious adverse events on the CT SAE Report Form to [COMPANY_007] Safet y.  
These requirements are delineated for 3 ty pes of events: (1) SAEs ; (2) nonserious adverse 
events (AEs); and (3) exposure to the study  intervention under study  during pregnancy  or 
breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must be 
completed in a consistent manner. AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for report ing of SAE information.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18846] SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study
intervention under stud y 
during pregnancy  or 
breastfeeding, and 
occupational exposureAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Occupational exposure is 
not recordedAll (and EDP supplemental 
form for EDP) 
Note: I nclude all SAEs 
associa ted with exposure 
during pregnancy  or 
breastfeeding. Include all 
AEs/SAEs associated with 
occupational exposure.
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  repo rts, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form/AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety. In this case, all participant identifiers, with the 
exception of the participant number, will be r edacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 77Severe: An event that prevents normal ever yday activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category  utilized for 
rating the intensit y of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the in itial transmission of the SAE data to the sponsor.
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the cri teria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention” for reporting 
purposes, as defined b ythe sponsor. In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this 
causal relationship in the source documents and CRF, and report such an 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18847] SAE Report Form and in accordance 
with the SAE reporting requirements.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested b y the 
sponsor to elucidate the nature and/or causalit y of the AE or SAE as fully as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers.
If a p articipant dies during participation in the study  or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings including histopathology .
New or updated information will be recorded in the origi nally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety  will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data 
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If asite receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next s ection) or to [COMPANY_007] Safety b y telephone.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18848] SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working, notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Repor t Form pages within the designated reporting 
time frames.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 8010.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information
10.4.1. Male Participant Reproductive Inclusion Criteria
No contraception methods are required for male participants in thi s study , as the highest dose 
of vupanorsen planned for this study  would result in maternal systemic exposure s via
seminal transfer well below (>5000 -fold) the exposure at the NOAEL for developmental 
toxicity  in nonclinical studies , including the conservative assumptions that an ASO 
ejaculate:sperm ratio would be 1 and there is 100% uptake b y the partner .
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and a t
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3 )
OR
Is a WOCBP and using an acceptable contraceptive method as described in 
Section 10.4.4 during the intervention period (for a minimum of [ADDRESS_18849] dose of study  intervention). The investigator should evaluate t he effectiveness of 
the contraceptive method in relationship to the first dose of study  intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy .
10.4.3. Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
1.Premenopausal female with 1 of the following:
Docume nted h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For indi viduals with permanent infertility  due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity ), investigator dis cretion should be 
applied to determining study  entry .
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 81Note: Documentation for any  of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history  
interview. The method of docum entation should be recorded in the participant’s medical 
record for the stud y.
2.Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. In addition, a
High FSH level in the postmenopausal rang e must be used to confirm a 
postmenopausal state in women under 60 years of age and not using hormonal 
contraception or HRT. 
Female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highl y effective con traception methods 
if they  wish to continue their HRT during the study . Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contraception Methods
Contraceptive use b y women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials. Women 
participants considered of childbearing potential must use at least one of the following 
acceptable contraception methods:
1.Implantab le progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion.
5.Vasectomized partner:
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed. If not, an additional highly  effective 
method of contraception should be used. The spermatogenesis cy cle is 
approximate ly 90 day s.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 826.Combined (estrogen -and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation:
Oral;
Intravaginal;
Transdermal;
Injectable.
7.Progestogen -only hormone contraception associated with inhibition of ovulation:
Oral;
Injectable.
8.Sexual abstinence:
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinen ce needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.
9.Progestogen -only oral hormonal contraception where inhibition of ovulation is not the 
primary  mode of action.
10.Male or female condom with or without spermicide.
11.Cervical cap, diaphragm, or sponge with spermicide.
12.A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 8310.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, 
susceptibility  to, and severity  and progression of disease. Therefore, where local 
regulations and IRBs/ECs allow, a blood sample will be collected for DNA anal ysis.
The scope of the gene tic research may  be narrow (eg,  1 or more candidate genes) or 
broad (eg, the entire genome), as appropriate to the scientific question under 
investigation.
The samples may  be analy zed as part of a multistudy  assessment of genetic factors 
involved in the r esponse to vupanorsen or study  interventions of this class to 
understand treatments for the disease(s) under study  or the disease(s) themselves.
The results of genetic analy ses may  be reported in CSR or in a separate study  
summary , or may  be used for inter nal decision making without being included in a 
study  report.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained as indicated:
Samples for banking will be stored indefinitel y or for another period as per local 
requirements.
Participants may  withdraw their consent for the storage and/or use of their Banked 
Biospecimens at an y time by [CONTACT_7328] a request to the investigator; in this case, an y 
remaining material will be destroy ed. Data alread y generated from the samples will 
be retained to protect the integrit y of existing analyses.
Banked Biospecimens will be labeled with a code. The key  between the code and the 
participant’s personally  identify ing information (eg, n ame, address) will be held at the 
study  site and will not be provided to the sample bank.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 8410.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up Assessments and 
Study Intervention Rechallenge Guidelines
Potential Cases of Drug -Induced Liver Inju ry
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI. 
Participants who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several days or weeks.  The increase in TBili typi[INVESTIGATOR_19955]/AL T is/are still elevated above 3 ×ULN (ie, AST/AL T and TBili values will be 
elevated within the same laboratory  sample). In rare instances, by  [CONTACT_20024], AST/ALT values might have decreased. This occurrence is still regarded as a 
potential DILI.  Therefore, ab normal elevations in either AST OR ALT in addition to TBili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be considered important medical events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions. Participants who present 
with the following laboratory  abnorma lities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR ALT values >3 ×ULN AND a TBili value 
>2×ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participants with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in t he definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller ).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18850]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_18851] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/I NR, total bile acids, and alkaline phosphatase. Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoa gulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology . A detailed history , including relevant information, 
such as review of ethanol, acetaminoph en/paracetamol (either by  [CONTACT_20025] a coformulated 
product in prescription or over -the-counter medications) , recreational drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected.  Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  tract) and coll ection of 
serum samples for acetaminophen /paracetamol drug and/or protein adduct levels may  be 
warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potenti al DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 8610.7. Appendix 7: ECG Findings of Potential Clinical Conc ern
ECG Findings That May Qualify as Adverse Events
Marked sinus brady cardia (rate <40bpm) lasting minutes.
New PR interval prolongation >280 msec.
New prolongation of QTcF to >480 msec (absolute) or by60msec from baseline.
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate <120 bpm.
New -onset ty peI second -degree (Wenckebach) AV block of >30 seconds’ 
duration.
Frequent PVCs, triplets, or short intervals (<30 seconds) of consecutive ventricular 
complexes.
ECG Findings That May Qualify as Serious Adverse Events
QTcF prolongation >500 msec.
New ST -Tchanges suggestive of myocardial ischemia.
New -onset left bundle branch block (QRS >120 msec).
New -onset right bundle branch block (QRS >120 msec).
Symptomatic brady cardia. 
Asystole:
In awake, s ymptom -free patients in sinus rhy thm, with documented periods of 
asystole 3.0 seconds or any  escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node; 
In awake, s ymptom -free patients with atri al fibrillation and brad ycardia with 
1or more pauses of at least 5 seconds or longer; 
Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained supraventricular tach ycardia (rate >120 bpm) (“sustained” = short
duration with relevant symptoms or lasting >1 minute).
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 87Ventricular rh ythms >30 seconds’ duration, including idioventricular rhy thm (HR 
<40 bpm), accelerated idioventricular rh ythm (HR 40 bpm to <100 bpm), and 
monomorphic/poly morphic ventricular tach ycardia (HR >100 bpm [such as 
torsades de pointes]).
TypeIIsecond -degree (Mobitz II) AVblock.
Complete (third -degree) heart block.
ECG Findings That Qualify as Serious Adverse Events
Change in pattern suggestive of new m yocardial infarction. 
Sustained ventricular tachy arrhy thmias (>30 seconds’ duration).
Second -or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.
Ventricular fibrillation/flutter.
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience.
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications to the investigator and [COMPANY_007] study team, and not to be considered as all inclusive of what to be 
reported as AEs/SAEs.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 8810.8. Appendix 8: Medical Device Adverse Events, Adverse Device Effects, Serious 
Adverse Events, and Device Deficiencies: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Definitions of a Medical Device Incident
The definitions and procedures detailed in this appendix are in accordance with I SO [ZIP_CODE]. 
Both the investigator and the sponsor will comply  with all local medical device reporting 
requirements.
The detection and documentation procedures described in this protocol apply  to all sponsor 
medical devices provided for use in the stud y (see Section 6.1.[ADDRESS_18852] of sponsor 
medical devices).
10.8.1. Definition of AE and ADE
AE and ADE Definition 
An AE is defined as an y untoward medical occurrence, unintended disease or 
injury , or untoward clinical signs (including abnormal laboratory  finding) in study  
participants, users, or other persons, whether or not related to the investigational 
medical device. This definition includes events related to the investigational 
medical device or comparator for study  participants, users , and other persons . This 
definition also include sevents considered related to procedures for stud y 
participants only . 
An ADE is defined as an adverse event related to the use of an investigational 
medical device. This definition includes any  adverse events resulting from 
insufficient or inadequate instructions for use, depl oyment, implantation, 
installation, or operation, or an y malfunction of the investigational medical device 
as well as an y event resulting from use error or from intentional misuse of the 
investigational medical device.
10.8.2. Definition of SAE, SADE, and Unanticipated Serious Adverse Device Effect
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , death 
due to progression of disease).
An SAE is an AE that:
a.Led to death 
b.Led to serious deterioration in the health of the participant, that either resulted in:
A life -threatening illness or injury . The term “life -threatening” in the definition of 
“serious” refers to an event in which the participant was at risk of death at the time 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18853] caused
death, if it were more severe .
A permanent impairment of a bod y structure or a body function .
Inpatient or prolonged hospi[INVESTIGATOR_059], planned hospi[INVESTIGATOR_272] a preexisting 
condition, or a procedure required b y the protocol, without serious deteriorati on in 
health, is not considered an SAE .
Medical or surgical intervention to prevent life -threatening illness or injury  or 
permanent impairment to a body  structure or a body  function .
c.Led to fetal distress, fetal death, or a congenital abnormality  or birt h defect .
SADE Definition
A SADE is defined as an adverse device effect that has resulted in an y of the 
consequences characteristic of a serious adverse event.
[LOCATION_003]DE Definition
A [LOCATION_003]DE is a serious adverse device effect which by  [CONTACT_5942], incidence, 
severit y or outcome has not been identified in the current version of the risk 
analysis management file .
10.8.3. Definition of Device Deficiency
Device Deficiency Definition
A device deficiency  is an inadequacy  of a medical device with respect to its 
identity , quality , durability , reliability , safet y, or performance. Device deficiencies 
include malfunctions, use errors, and inadequate labeling.
10.8.4. Recording/Reporting and Follow -up of AEs and/or SAEs and Device 
Deficiencies
AE, SAE and Device Deficiency Recording
When an AE/SAE/device deficiency  occurs, it is the responsibility  of the 
investigator to review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  
reports, and diagnostic reports) related to the event.
The investigator will then record all relevan t AE/SAE/device deficiency  
information in the participant’s medical records, in accordance with the 
investigator’s normal clinical practice and on the appropriate form of the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_19956]’s 
medical records to [COMPANY_007] Safety  in lieu of following the reporting process described 
in the I P manual and completing the Medical Device Complaint CRF.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 90There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] S afety . In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event ba sed on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
For device deficiencies, it is very  important that the investigator describes any  
corrective o r remedial actions taken to prevent recurrence of the incident.
oA remedial action is an y action other than routine maintenance or servicing 
of a medical device where such action is necessary to prevent recurrence of 
a device deficiency . This includes any  amendment to the device design to 
prevent recurrence.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE/SAE/device deficiency  
reported during the stud y and assign it to 1 of the following categories:
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents norma l every day activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category  utilized for 
rating the intensit y of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as severe .
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE/device deficiency .
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The inv estigator will also consult the IB in his/her assessment.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 91For each AE/SAE/device deficiency , the investigator must document in the 
medical notes that he/she has reviewed the AE/SAE/device deficiency  and has 
provided an assessment of causalit y.
There may  besituations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator alway s make an assessment of causality for 
every  event before the ini tial transmission of the SAE data to the sponsor.
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements
Follow -up of AE/SAE/ Device Deficiency
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested b y the 
sponsor to elucidate the nature and/or causalit y of the AE/SAE/device deficiency  as 
fully  as possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare pr oviders.
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings including histopathology .
New or updated information will be record ed in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information .
10.8.5. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety  will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data 
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to exist ing data.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 92If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE fo rm (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working, notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign th e CT SAE Report Form pages within the designated reporting 
time frames.
10.8.6. Reporting of SADEs
SADE Reporting to [COMPANY_007] Safety
NOTE: There are additional reporting obligations for medical device incidents that are 
potentially  related to SAEs that must fulfill the legal responsibility  to notify  appropriate 
regulatory  authorities and other entities about certain safet y information relatin g to medical 
devices being used in clinical studies. 
Any device deficiency  that is associated with an SAE must be reported to the 
sponsor within 24 hours after the investigator determines that the event meets the 
definition of a device deficiency .
The sponsor shall review all device deficiencies and determine and document in 
writing whether they  could have led to an SAE. These shall be reported to the 
regulatory  authorities and I RBs/ECs as required by  [CONTACT_2091].
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 9310.9. Appendix 9: Country -specific Requirements
Not applicable.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 9410.10. Appendix 10: Evaluation of Participants with Decreased Platelet Count

Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 9510.11. Appendix 11: Evaluation of Participants with Worsening Renal Function

Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 9610.12. Appendix 12: Management of Elevated AST or ALT

Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 9710.13. Appendix 13: Alternative Measures During Public Emergencies
The alternative study  measures described in this secti onmay be followed during public 
emergencies, including the COVID -19 pandemic. This appendix applies for the duration of 
the COVID -19 pandemi c globall y and will become effective for other public emergencies 
only upon written notification from [COMPANY_007]. This appendix is not intended for use during 
screening. 
Consult with the site monitor prior to utilizing this appendix.
Use of these alternative study  measures are expected to cease upon the return of business as 
usual circumstances (including the lifting of an y quarantines and travel bans/advisories).
10.13.1. Eligibility
While SARS -CoV2 testing is not mandated for this study , local clinical practice stand ards for 
testing should be followed. Participants with active infections are excluded from study  
participation as per Exclusion Criterion 9 (other medical condition or laboratory  abnormality  
that may  increase the risk of study  participation or, in the inve stigator’s judgment, make the 
participant inappropriate for the stud y). When the infection resolves, the participant may  be 
considered for re -screening if the participant has not been randomized.
10.13.2. Home Health Visits
A home health care service may be utilized to facilitate scheduled visits per the Schedule of 
Activities . Home health visits include a healthcare provider conducting an in -person study  
visit at the participant’s location, rather than an in -person study  visit at the site. If the 
participant does not allow blood draws for laboratory assessments, theparticipant will 
be discontinued from study intervention. The following may  be performed during a home 
health visit:
Obtain vital signs (seated blood pressure and pulse rate).
Obtain weight.
Draw blood for laboratory  assessments. (See Section [IP_ADDRESS] and Section 10.13.7 ).
Collect urine specimen for laboratory  assessments. (See Section [IP_ADDRESS] ).
Perform 12 -lead ECG.
Review and record stud y intervention, including compliance (review dosing diary , if 
available) and missed doses.
Review and record an y AEs and SAEs s ince the last contact. Refer to Section 8.3.
Review and record an y new concomitant medications or changes in concomitant 
medications since the last contact.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 98Review and record contraceptive method and results of pregnancy  testing , if 
applicable . Con firm that the participant is adhering to the contraception method(s) 
required in the protocol. Refer to Appendix [ADDRESS_18854] data points. If the participant does not allow blood 
draws for laboratory assessm ents, theparticipant will be discontinued from study 
intervention. Telehealth includes the exchange of healthcare information and services via 
telecommunication technologies (eg, audio, video, video -conferencing software) remotel y, 
allowing the participan t and the investigator to communicate on aspects of clinical care, 
including medical advice, reminders, education, and safet y monitoring. The following 
assessments must be performed during a telehealth visit:
Review and record stud y intervention(s), includ ing compliance and missed doses.
Review and record an y AEs and SAEs since the last contact. Refer to Section 8.3.
Review and record an y new concomitant medications or changes in concomitant 
medications since the last contact.
Review and record contraceptive method and results of pregnancy  testing , if 
applicable . Confirm that the participant is adhering to the contraception method(s) 
required in the protocol. 
Study  participants must be reminded to promptl y notify  site staff about an y change in their 
health status.
10.13.4. Alternative Facilities for Safety Assessments
[IP_ADDRESS]. Laboratory Testing
All specimen collections under this appendix will be performed by[CONTACT_20026] .It is preferred that participants utilize home health care 
for safety  and efficacy  laboratory  evaluations. Use of local laboratories will be allowed onl y 
if on site or home health care measures cannot be used. If a study  participant is unable to visit 
the site or have home health utilized for protocol -specified laboratory  evaluations, testing 
may be conducted at a local laboratory  if permitted by  [CONTACT_427]. The local laboratory  
may be a standalone institution or within a hospi[INVESTIGATOR_307].
If a local laboratory  is used, qualified study  site personnel must order, receive, and review 
results. Site staff must collect the local laboratory  reference ranges and 
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 99certifications/accreditations for filing at the site. Laborator y test results are to be provided to 
the site staff as soon as possible. The local laboratory reports should be filed in the 
participant’s source documents/medical records. Relevant data from the local laboratory  
report should be recorded on the CRF.
If a participant requiring pregnancy  testing cannot visit a local laboratory  for pregnancy  
testing or engage in home health care, a home urine pregnancy  testing kit with a sensitivity  of 
at least 25 mIU/mL  may  be used by  [CONTACT_20027] h ome, if compliant 
with local regulatory  requirements. The pregnancy  test outcome should be documented in the 
participant’s source documents/medical records and relevant data recorded on the CRF. 
Confirm that the participant is adhering to the contraception method(s) required in the 
protocol.
[IP_ADDRESS]. Imaging
If the participant is unable to visit the study  site for MRI -PDFF assessment, the participant 
may visit an alternative facility  to have the MRI -PDFF assessment performed. Qualified 
study  site personnel must orde r, receive, and review results.
[IP_ADDRESS]. Electrocardiograms
All [ADDRESS_18855] be kept in the 
participant’s source documents/medical records.
If in-home dosing is instituted, a dosing diary  will be provided to the participant for 
documenting compliance. The dosing diary  should be returned to the site for review as soon 
as possible.
The following is recommended for the administration of study  intervention for participants 
who have active confirmed (positive by  [CONTACT_20028] y-approved te st) or presumed (test 
pending/clinical suspi[INVESTIGATOR_2798]) SARS -CoV2 i nfection:
For s ymptomatic participants with active SARS -CoV2 infection, study  intervention 
should be delay ed for at least 14 day s from the start of sy mptoms. This delay  is 
intended to allow the resolution of sy mptoms of SARS -CoV2 infection.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 100Prior to restar ting treatment, the participant should be afebrile for [ADDRESS_18856] recovered for a minimum of 72 hours.
Notify  the study  team when treatment is restarted.
Continue to record any concomitant medication administered for treatment of 
SARS -CoV2 infection.
10.13.6. Adverse Events and Serious Adverse Events
If a participant has COVID -[ADDRESS_18857] process . If a participant has positive 
COVID -19(SARS -CoV2) test, even if asymptomatic, this should be recorded as an AE (see 
Section 8.3).
Study  treatment should continue unless the investigat or/treating phy sician is concerned about 
the safet y of the participant, in which case temporary or permanent discontinuation may be 
required.
It is recommended that the investigator discuss temporary  or permanent discontinuation of 
study  intervention with the study  medical monitor.
10.13.7. Efficacy Assessments
There will be no alternative measures for efficacy  assessments other than what is in the 
protocol, Section 8.1.It ispreferred that participants utilize home health care for efficacy  
laboratory  evaluations. Use of local laboratories will be allowed only  if on site or home 
health care measures cannot be used. If a study  participant is unable to visit the site or have 
home health utilized for protocol -specified laboratory  evaluations, testing may  be conducted 
at a local laboratory  if permitted by  [CONTACT_427].
10.13.8. Independent Oversight Committees
The External Data Monitoring Committee will be informed when this appendix h as been 
utilized.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page [ZIP_CODE].14. Appendix 1 4: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
A/C albumin/creatinine
ADA anti-drug antibodies
ADE adverse device effect
AE adverse event
AESI adverse events of special interest
ALT alanine aminotransferase
ANGPTL [ADDRESS_18858] aspartate aminotransferase
AUC area under the concentration -time curve
AV atrioventricular
-hCG beta-human chorionic gonadotropin
bpm beats per minute
BL baseline
BUN blood urea nitrogen
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -Epi [INVESTIGATOR_19957] -Epi[INVESTIGATOR_19958] -[ADDRESS_18859]
HR heart rate
HRT hormone replacement therap y
hsCRP high-sensitivity  C-reactive protein
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IDL intermediate densit y lipoproteins
IMP investigational medicinal product
IND investigational new drug
INR international normalized ratio
IP manual investigational product manual
IPAL Investigational Product Accountability  Log
IRB institutional review board
IRT interactive response technology
ISO International Organization for Standardization
IWR interactive web-based response
K2 dipotassium
LDL low-density  lipoprotein
LDL -C low-density  lipoprotein cholesterol
LFT liver function test
LLN lower limit of normal
Lp(a) lipoprotein(a)
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, [ADDRESS_18860] squares
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MMRM Mixed Model Repeated Measurements
MOE methoxy ethyl
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid 
msec millisecond
n number
N/A not applicable
NAFLD nonalcoholic fatt y liver disease
NASH nonalcoholic steatohepatitis
NIMP noninvestigational medicinal product
NOAEL no-observed -adverse -effect level
Non-HDL -C non-high-density  lipoprotein cholesterol
PDFF proton density  fat fraction
PCSK9 proprotein convertase subtilisin/kexin ty pe 9
PD pharmacod ynamic(s)
PI [INVESTIGATOR_19959](s)
PT prothrombin time
PVC premature ventricular contraction/complex
QTc corrected QT
QTcF corrected QT (Fridericia method)
QW every  week
Q2W every  [ADDRESS_18861]
SAE serious adverse event
SAP statistical analy sis plan
SARS -CoV2 severe acute respi[INVESTIGATOR_19960] 2
SC subcutaneous(l y)
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safet y document
S[LOCATION_003]R suspected unexpected serious adverse reaction
TBili total bilirubin
TE treatment -emergent
TEADA treatment -emergent anti -drug antibodies
TEAE treatment -emergent adverse event
TG triglyceride(s)
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 104Abbreviation Term
TIMI Thromboly sis in My ocardial I nfarction
T2DM type 2 diabetes
Tmax time to reach C max
UACR urine albumin: creatinine ratio
ULN upper limit of normal
US [LOCATION_002]
[LOCATION_003]DE unanticipated serious adverse device effect
VLDL very low-densit y lipoproteins
VLDL -C Very  low-density  lipoprotein cholesterol
WBC white blood cell
WOCBP woman of childbearing potential
11.REFERENCES
     
1.Dewey  FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of 
ANGPTL 3 and cardiovascular disease. N Engl J Med 2017;377(3):211 -21.
2.Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4 -year 
cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. 
JAMA 2010;304(12):1350 -7.
3.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NL A/PCNA 
Guideline on the managem ent of blood cholesterol. J Am Coll Cardiol 
2019;73:e285 -350.
4.Libb y P. The forgotten majority: unfinished business in cardiovascular risk reduction. 
JAm Coll Cardiol 2005;46(7):1225 -8.
5.Pi[INVESTIGATOR_17968] T, Girman CJ, Sacks FM, et al. Non -high-density  lipoprot ein cholesterol and 
apolipoprotein B in the prediction of coronary  heart disease in men. Circulation 
2005;112(12):3375 -83.
6.Arsenault BJ, Rana JS, Stroes ES, et al. Bey ond low -density  lipoprotein cholesterol: 
respective contributions of non -high-densit y lipoprotein cholesterol levels, trigl ycerides, 
and the total cholesterol/high -densit y lipoprotein cholesterol ratio to coronary  heart 
disease risk in apparentl y healthy men and women. J Am Coll Cardiol 
2009;55(1):[ADDRESS_18862] BG. Trigl yceride -rich lipoproteins and atherosclerotic cardiovascular 
disease: new insights from epi[INVESTIGATOR_623] , genetics, and biology . Circ Res 
2016;118(4):547 -63.
Vupanorsen
Protocol C4491011
Final Protocol Amendment 1, 18 September 2020
PFIZER CONFIDENTIAL
Page 1058.Marston NA, Giugliano RP, I m K, et al. Association between trigl yceride lowering and 
reduction of cardiovascul ar risk across multiple lipid -lowering therapeutic classes: a 
systemic review and meta -regression anal ysis of randomized controlled trials. 
Circulation 2019;140(16):1308 -17.
9.Bhatt DL, Steg PG, Miller M, et al Cardiovascular risk reduction with icosapent ethyl 
for h ypertrigl yceridemia. N Engl J Med 2019;380(1):[ADDRESS_18863] BG. Nonfasting mild -to-moderate 
hypertrigly ceridemia and risk of acute pancreatitis. JAMA I ntern Med 
2016;176(12):1834 -42.
11.Shimizugawa T, Ono M, Sh imamura M, et al. ANGPTL 3 decreases very  low density  
lipoprotein trigl yceride clearance b y inhibition of lipoprotein lipase. J Bio Chem 2002; 
277(37):[ZIP_CODE] -8.
12.Musunuru K, Pi[INVESTIGATOR_19961], Do R. Exome sequencing, ANGPTL3 mutations, and 
familial combined h ypolipi[INVESTIGATOR_035]. N Engl J Med 2010;363(23):2220 -7.
13.Miniocci I , Santini S, Cantisani V, et al. Clinical characteristics and plasma lipi[INVESTIGATOR_19962]: a pooled anal ysis. J L ipid Res 
2013;54(12):3481 -90.
14.Gaudet D, Gipe DA, Pordy  R, et al. ANGPTL3 inhibition in homozy gous familial 
hypercholesterolemia. N Engl J Med 2017;377(3):[ADDRESS_18864] 
coronary  artery  disease. J Am Coll Cardiol 2017;69(16):2 054-63.
16.Chi X, Gatti P, Papoian T. Safet y of antisense ologionucleotide and siRNA -based 
therapeutics. Drug Discov Today  2017;22(5):[ADDRESS_18865], Baker BF, Xia S, et al. Integrated assessment of the clinical performance of 
GalNAc 3-conjugated 2’O -methoxy ethyl chimeric antisense oligonucleotides: I . human 
volunteer experience. Nucleic Acid Ther 2019;29(1):16 -32.
18.van Meer L, Moerland M, Gallagher J, et al. Injection site reactions after subcutaneous 
oligonucleotide therap y. Br J Clin Pharmacol 201 6;82(2):340 -51.